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TumorigenesisPotassium channels are a diverse group of pore-forming transmembrane proteins that selectively facilitate potas-
sium ﬂow through an electrochemical gradient. They participate in the control of the membrane potential and
cell excitability in addition to different cell functions such as cell volume regulation, proliferation, cell migration,
angiogenesis aswell as apoptosis. Because these physiological processes are essential for the correct cell function,
K+ channels have been associated with a growing number of diseases including cancer. In fact, different K+
channel families such as the voltage-gated K+ channels, the ether à-go-go K+ channels, the two pore domain
K+ channels and the Ca2+-activated K+ channels have been associated to tumor biology. Potassium channels
have a role in neoplastic cell-cycle progression and their expression has been found abnormal in many types of
tumors and cancer cells. In addition, the expression and activity of speciﬁc K+ channels have shown a signiﬁcant
correlation with the tumor malignancy grade. The aim of this overview is to summarize published data on K+
channels that exhibit oncogenic properties and have been linked to amoremalignant cancer phenotype. This ar-
ticle is part of a Special Issue entitled: Membrane channels and transporters in cancers.
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Potassium (K+) channels are themost diverse class of ion channels in
the plasmamembrane and are encoded bymore than 75 different genes.
They can be classiﬁed according to several criteria, including the stimulus
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into four main families: voltage-gated K+ channels, calcium-activated
K+ channels, inward-rectiﬁer K+ channels and two-pore-domain K+
channels. The voltage-dependent K+ channel (Kv) family can be
subdivided into Kv1–4 channels (Shaker, Shab, Shaw and Shal-like sub-
units), Kv7 channels (KCNQ), the silent Kv5, Kv6, Kv8 and Kv9 subunits
(modulators) and Kv10–12 channels (EAG-like) [1,2]. K+ currents play
a key role in multiple cellular functions such as the maintenance of
resting membrane potential and the active repolarization of the action
potential, the regulation of cell volume, differentiation, proliferation,
migration and apoptosis. Therefore, K+ channels control the electrical
excitability of nerves and muscles, affect neurotransmitter and insulin
release, and modulate the immune response and other physiological
processes [1,3,4]. Potassium channels are widely distributed in a variety
of healthy and cancer cells. They are involved in physiological cell prolif-
eration and neoplastic growth as well as tumor progression and malig-
nancy. In fact, it has been increasingly documented that K+ channels
have an oncogenic potential [5–22]. The subfamilies of K+ channels
that have been correlated with the proliferation of tumor cells are the
shaker-type voltage gated K+ channels [9,23–25], the ether-à-go-go
voltage-gated K+ channels [7,26–30], the two-pore domain K+ channels
[31–33], and the Ca2+-activated K+ channels [34–37]. In this complex
scenario, the main K+ channels subtypes that are addressed in this
issue are those that have been unequivocally associated with malignant
progression. Thus, wewill concentrate on the Shaker-like, EAG and two-
pore domain subgroups (Fig. 1).1.1. Shaker potassium channels
The voltage-gated potassium channels of the Shaker family (Kv1)
have been reported to be crucial for the proliferation of healthy and
cancerous cells [9,10,14,38–43]. Speciﬁcally, Kv1.3 and Kv1.5 arewidely
implicated in the development of different tumors [22–24,44–50]. From
the extensive published data on Kv1.3 and Kv1.5 in human cancers, we
will summarize the evidence regarding their role in the progression
toward a more malignant phenotype.S1 S2 S4 S5 S6S3
NH2
COOH
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Fig. 1. A. Shaker potassium channels have six transmembrane segments (S1–S6) and one
pore (P) between segments S5–S6. The positively charged fourth transmembrane
segment (S4) acts as a sensor for changes in the membrane potential and both, N- and
C-terminus are intracellular. B. Ether-à-go-go voltage-gated potassium channels hold a
very similar membrane-spanning region than shaker K+ channels with S1–S4 contribut-
ing to the voltage sensor domain and S5–S6 alongwith the intervening pore loop forming
the pore domain. But ether-à-go-go K+ channels show large intracellular NH2 and COOH
terminus that contain a Per-Arnt-Sim (PAS) domain and a cyclic nucleotide binding
domain (cNBD), respectively. C. Two-pore domain K+ channels (K2P) possess four distinct
transmembrane segments (S1–S4), and two pore sequences (P1–P2) with both N- and C-
termini positioned into the cytosol. Each pore domain contains an outward and an inward
membrane spanning-helix ﬂanking the potassium ion-selectivity ﬁlter segment and the
membrane-entrant pore helix.1.1.1. Voltage-activated potassium channel 1.3 (Kv1.3)
Voltage-gated potassium channel, shaker-related subfamily mem-
ber 3, known as Kv1.3, is a protein encoded by the KCNA3 gene in
humans. Outward delayed rectiﬁer Kv1.3 currents are typically activat-
ed at a membrane voltage of −35 mV. These currents show C-type
inactivation as well as a characteristic cumulative inactivation. Kv1.3
channels are ubiquitously distributed, being expressed in B [51] and T
lymphocytes [5], macrophages [42], the olfactory bulb [52], as well as
epithelia [53] and several other tissues [54,55]. Kv1.3 channels contrib-
ute to the activation and proliferation of both B [51] and T lymphocytes
[56] and they are present at the immunological synapse during antigen
presentation [57]. Thus, they have been associated with autoimmune
diseases [58,59]. Although Kv1.3 has been primarily detected at the
plasma membrane, it is also present in the inner mitochondrial
membrane (IMM) in lymphocytes [60], where it contributes to apopto-
sis [61]. Kv1.3 also participates in the insulin signaling pathway and has
been associated with insulin sensitivity [62] and obesity [63].
In recent years, the importance of voltage-gated K+ channels (Kv) in
cancer biology has gained attention due to their identiﬁcation as poten-
tial novel tumormarkers [17,21] (Table 1). First, the aberrant expression
of Kv1.3 has been detected in many cancer cells [17,19,23,24,47,50,55,
64–73]. Normal prostate samples show high positive immunostaining
of Kv1.3 protein, whereas human prostate cancer cell lines (DU145,
PC3, MDA-PCA-2B, and LNCaP) display moderate to strong Kv1.3 levels
[23]. Kv1.3 currents have also been detected in the highly metastatic
Mat-LyLu and theweaklymetastatic AT-2 rat prostate cell lines. Howev-
er, these two cell lines with markedly different metastatic abilities
exhibit Kv1.3 currents with different biophysical properties. The MAT-
LyLu cells show lower current densities compared to the AT-2 cells.
Therefore, the Kv1.3 channels in MAT-LyLu cells may be less active
than those in the AT-2 cell line [68]. This fact, together with the
exclusive expression of voltage-gated sodium channels in MAT-LyLu
cells [74], suggests an important role of voltage-dependent ion channels
in cancer metastasis [75,76]. Similarly, the strongly metastatic human
prostate cell line PC3 shows lower Kv1.3 currents than the LNCaP cell
line, which is weakly metastatic. Therefore, there is an inverse correla-
tion between thepresence of Kv1.3 and themetastatic ability of prostate
cancer cell lines [69]. Moreover, normal prostate tissue and benign
prostatic hyperplasia show high expression of Kv1.3, but only half of
the tested prostate cancer (Pca) samples show similarly high expres-
sion. Thus, Kv1.3 protein levels inversely correlate with high tumor
grade and a poor prognosis in Pca. All of these data demonstrate that
the presence of Kv1.3 may serve as a useful diagnostic or prognostic
marker for prostate cancer [67]. Prostate and breast cancers show a
similar ion channel expression proﬁle, consistent with their similar
cell growth dependence from hormones. In fact, Kv1.3 expression levels
have been reported to be lower in cancer samples [77] and grade III
tumors [70] than in normal tissues, and the methylation of the KCNA3
promoter is also increased in tumors [70]. Although the molecular
mechanism is unknown, promoter methylation has been associated
with silencing gene expression in other cancer cells [78]. Because the
methylation status of KCNA3 is associated with poorly differentiated
tumors and younger patients, Kv1.3 is linked to cancer malignancy
[70]. Kv1.3 protein is not observed in healthy breast tissues, whereas
most cancer biopsies show increased Kv1.3 [47,64]. The K+ channel
opener minoxidil stimulates the proliferation of the MCF-7 breast
carcinoma cell line. In contrast, different blockers such as dequalinium,
amiodarone [47], and others [45] inhibit the proliferation of MCF-7
cells. K+ channel blockers also potentiate the growth-inhibitory effects
of tamoxifen in human breast, prostate, and colon cancer cell lines [47].
In addition, the expression of Kv1.3 and Kv1.5 increases concomitantly
with increasing numbers of inﬁltrating inﬂammatory cells surrounding
mammary duct carcinomas [64]. Another study of immortalized
mammary epithelial cells determined that the expression of Kv1.3 also
varies with the stage of the cancer. The mRNA expression of Kv1.3 in
the weakly tumorigenic M13SV1R2 mammary epithelial cell line is
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cells and less than that of highly tumorigenic M13SV1R2-N1 cells. On
the other hand, the protein levels of the Kv1.3 subunit are signiﬁcantly
increased in the M13SV1R2 and M13SV1R2-N1 mammary epithelial
cell lines compared to normal M13SV1 mammary epithelial cells.
Furthermore, in contrast to the mRNA, quantiﬁcation analyses revealed
that the Kv1.3 protein was induced in the highly tumorigenic
M13SV1R2-N1 mammary cells. Although Kv1.3 protein expression
does not correlate with the level of Kv1.3 mRNA, Kv1.3 is remodeled
in both tumorigenic breast cell lines. Furthermore, K+ channel blockers
inhibit the proliferation of M13SV1R2 and M13SV1R2-N1 cells. Kv1.3
protein levels are low in normal human breast tissue and high in both
T2- and T3-stage breast cancer tissues. Therefore, the level of Kv1.3
protein expression is differentially correlated with the stage of breast
cancer [71].
An analysis of human smooth muscle tumors compared to their
healthy counterparts has reported a correlation between the expression
of Kv1.3 and tumor aggressiveness. Kv1.3 channels are poorly expressed
in control muscles and human samples of indolent leiomyoma (LM),
which is a benign uterine tumor. However, the expression of Kv1.3 is
induced inmalignant leiomyosarcoma (LMS), an aggressive retroperito-
neal neoplasm [73]. In human skeletal muscle sarcomas, the differential
expression of Kv1.3 channels depending on the aggressiveness has also
been detected. Although the presence of Kv1.3 is believed to be low in
healthy adult samples and absent in the less aggressive embryonal
rhabdomyosarcoma (ERMS), it increases notably in aggressive alveolar
rhabdomyosarcomas (ARMS). Therefore, the expression of Kv1.3 is
altered during both smooth and skeletal carcinogenesis and positively
correlates with tumor malignancy [55].
On the contrary, although Kv1.3 is induced in gliomas [64], it does
not show a differential expression pattern among diverse types of glio-
mas or a connection between malignancy and channel expression [50].
This lack of association between Kv1.3 levels and cancer aggressiveness
has also been described in human lymphomas. The expression of Kv1.3
has been analyzed in a low aggressiveness non-Hodgkin's lymphoma
(follicular B-cell lymphoma) and other non-Hodgkin's lymphomas
with high aggressiveness (mantle, T-cell, diffuse large B-cell and
anaplastic lymphomas). Control lymph nodes express heterogeneous
levels of Kv1.3, demonstrating different states of cell activation. More-
over, the abundance of Kv1.3 does not correlate with either the state
of de-differentiation or the nature of lymphomatous cells [79].
Kv1.3 is expressed in the plasma membrane but also in the IMM
(mitoKv1.3) of lymphocytes where it mediates apoptosis [80].
MitoKv1.3 physically interacts in a toxin-like mode with Bax, which is
a proapoptotic protein of the Bcl-2 family. Bax inhibits Kv1.3 via interac-
tion of lysine 128 with the channel pore, resulting in IMM hyperpolari-
zation and the release of reactive oxygen species (ROS). ROSmight play
multiple roles in apoptosis such as thedissociation of cytochrome c from
the IMM and the permeability transition pore (PTP) activation [61,81].
In addition, mitoKv1.3 has been found in macrophages [82] as well as
in prostate cancer cell line PC3 and in breast cancer cell line MCF-7
[83] suggesting that this channel might play a role in the apoptotic
signaling in other cells. Interestingly, inhibition of mitoKv1.3 could be
used to treat chronic lymphocytic leukemia (B-CLL). Membrane-
permeable Kv1.3 inhibitors such as Psora-4, PAP-1 and clofazimine
induce apoptosis in B-CLL cells by directly targeting the mitochondrial
channel. Importantly, pathologic B-CLLs express higher levels of Kv1.3
protein and are speciﬁcally sensitive to treatment, whereas healthy B
cells, which express less Kv1.3, are resistant to these drugs. Thus,
Kv1.3 inhibitors may be promising therapeutic tools for the treatment
of B-CLL patients [84] whereas other mitochondrial ion channels like
Kv1.5, BKCa and TASK-3 may have also a potential role in the regulation
of apoptosis [85–87]. An extensive immunohistochemistry study has
also been revealed an increase of Kv1.3 protein in colon adenocarcino-
ma and a decrease in ovary, kidney, bladder and lung carcinomas [64].
Different studies have demonstrated that the expression of Kv1.3decreases in most cancers [64,88]. The anti-proliferative role of Kv1.3
has been tested in vivo in a mice xenograft model. In this study,
development of A549 injected-human lung adenocarcinoma growth is
suppressed by applying the selective Kv1.3 blocker margatoxin [13].
All these data, together with the fact that Kv1.3 suppression prevents
apoptosis [83], suggest that the Kv1.3 channel may act as a tumor
suppressor, although its role in tumor development is still unclear.
1.1.2. Voltage-activated potassium channel 1.5 (Kv1.5)
The Kv1.5 channel, encoded by KCNA5, is another member of the
voltage-gated, shaker-related family. Kv1.5 displays outward delayer
rectifying currents with a rapid activation at a more depolarizing
membrane potential than Kv1.3 (−25 mV). Unlike Kv1.3, Kv1.5 inacti-
vation is slow and lacks cumulative inactivation. Both Kv1.3 and Kv1.5
are inhibited by general K+ channel blockers such as 4-aminopyridine
(4-AP) and tetraethylammonium (TEA) [89]. While Psora-4 is a potent
inhibitor of Kv1.3 and Kv1.5 [90], charybdotoxin [91], margatoxin [92]
and the anemone peptide ShK are effective only against Kv1.3 channels
[93]. In contrast, Kv1.5 has no known speciﬁc pharmacology, and it is
highly insensitive to most Kv1.3 blockers. However, a combination of
these chemical compounds makes possible to distinguish Kv1.3
currents fromKv1.5 currents. Similar to Kv1.3, Kv1.5 channels arewide-
ly expressed [94–96]. For example, Kv1.5 expression has been observed
in skeletal and smooth muscles and the immune system, kidneys and
heart [42,43,73]. Kv1.5 is involved in the cardiac action potential, and
defects in KCNA5 are the cause of familial atrial ﬁbrillation [97] and
sudden cardiac death [98]. It is also implicated in the activation, differ-
entiation and proliferation of different cell types [8,11,40,43,48,
99–102]. Interestingly, the Kv1.3 and Kv1.5 subunits interact to gener-
ate functional heterotetrameric channels that are relevant in immunity
[82,103].
Many studies have found that the expression of Kv1.5 is remodeled
in human cancer cells from the lungs [72], skeletal muscles [55], central
nervous system [50], kidneys, pancreas, and skin [64]. The expression of
Kv1.5 is almost absent fromhealthy smoothmuscle samples but hetero-
geneous and faint in indolent LM. In contrast, Kv1.5 displays a homoge-
neous low-level expression in aggressive LMS samples. Thus, there is a
positive correlation between the expression of Kv1.5 and the aggres-
siveness of smooth muscle neoplasms [73]. Similarly, Kv1.5 protein
staining is weak in healthy adult skeletal muscle, heterogeneous in
ERMS specimens, and homogeneously high in aggressive ARMS
samples. Therefore, the expression of Kv1.5 also increases with increas-
ing tumor aggressiveness grade in ERMS and ARMS [55].
Gliomas can emerge from both astrocytic and oligodendrocytic
lineages to generate low and high malignancy grades, respectively.
The expression of Kv1.5 channels has been reported to be high in astro-
cytomas butmoderate in oligodendrogliomas and low in glioblastomas,
which represent another class of high malignancy glioma [50]. Another
report has also found that astrocytomas had stronger Kv1.5 immuno-
staining than glioblastomas [64]. Thus, the expression of Kv1.5 inversely
correlates with the malignancy grade of glioma entities and may be a
good candidate for detection and outcomeprediction [50,64].Moreover,
glioblastoma patients with higher levels of Kv1.5 show slightly better
overall survival [104]. Similar results have been observed in non-
Hodgkin's lymphomas, where Kv1.5 expression is inversely correlated
with the grade of clinical malignancy. Unlike Kv1.3, the abundance of
Kv1.5 was more homogeneous in normal and lymphoma samples. The
levels of Kv1.5 channels are low in normal lymph nodes but noticeable
in indolent follicular B-cell lymphomas. However, several tested aggres-
sive non-Hodgkin's lymphomas (mantle, T-cell, diffuse large B-cell and
anaplastic lymphomas) exhibit low to moderate levels of Kv1.5, similar
to control lymph nodes. The link between the level of the Kv1.5 protein
and the aggressiveness of tumorsmay convert this channel into a useful
biomarker in the diagnosis or prognosis of some lymphomas [79].
Finally, colon, stomach, pancreatic, bladder, skin, and mammary
duct carcinomas express higher levels of Kv1.5 than the healthy tissues,
Table 1
Potassium channels related with malignant progression of cancer.
Family Channel Tissue Tumors/cancer cell lines Evidences Reference
Shaker Kv1.3 Prostate Normal human prostate specimens
Benign prostatic hyperplasia (BPH) samples
Primary human prostate cancer (Pca) samples
Reduced expression in higher tumor
grade/stage
[23]
Weakly metastatic AT-2 rat prostate cell line
Highly mestastatic Mat-LyLu rat prostate cell line
Lower current density in Mat-LyLu cells [68]
Weakly metastatic LNCaP human prostate cell line
Strongly metastatic PC3 human prostate cell line
Lower current density in PC3 cells [69]
Breast Breast adenocarcinoma MCF-7 cell line
Normal breast epithelial MCF cell line
Normal human breast epithelial primary cells
(HMEpC)
Lower expression in grade III tumors
Increased methylation of the KCNA3 promoter
[70]
Normal M13SV1 mammary epithelial cell line
Weakly tumorigenic M13SV1R2 mammary
epithelial cell line
Highly tumorigenic M13SV1R2-N1 mammary
tgsecqizepithelial cells
Increased mRNA expression in M13SV1R2 cells
Induced protein levels in M13SV1R2-N1 cells
[71]
Smooth Muscle Benign Leiomyoma (LM)
Aggressive Leiomyosarcoma (LMS)
Induced expression in malignant LMS [73]
Skeletal Muscle Embryonal Rabdomyosarcoma (ERMS)
Aggressive Alveolar Rabdomyosarcoma (ARMS)
Increased expression in aggressive ARMS [55]
Shaker Kv1.3 B lymphocytes Chronic lymphocytic leukemia (B-CLL) Increased protein expression [84]
Kv1.5 Smooth Muscle Benign Leiomyoma (LM)
Aggressive Leiomyosarcoma (LMS)
Higher and more homogeneous
expression in aggressive LMS
[73]
Skeletal Muscle Less aggressive Embryonal Rabdomyosarcoma (ERMS)
Aggressive Alveolar Rabdomyosarcoma (ARMS)
Higher and more homogeneous
expression in aggressive ARMS
[55]
Brain Low malignancy astrocytoma
High malignancy oligodendroglioma
High malignancy glioblastoma
High expression in astrocytoma
Moderate expression oligodendroglioma
Low expression glioblastoma
[50,64]
Lymph Node Low aggressiveness non-Hodgkin's lymphoma
(Follicular B-cell)
High aggressiveness non-Hodgkin's lymphomas
(Mantle, T-cell, diffuse large B-cell, anaplastic)
Higher abundance in indolent
Follicular B-cell non-Hodgkin's lymphoma
[79]
EAG hEAG1 Head/neck Head and Neck Squamous Cell Carcinoma (HNSCC) Higher expression in advanced
stages of HNSCC tumors
[141]
EAG hEAG1 Colon T84 colonic cancer cell lines
Crypt cells of mice colon treated with
carcinogenic agents
Human colorectal adenocarcinomas with diverse
diagnosis
Increased mRNA expression in mice colon
treated with DMH/MNU carcinogenic agents
Gene ampliﬁcation is associated
with adverse outcome in tumor samples
[135,147]
Colon Colorectal adenoma tissues
Paired non-cancerous matched tissues
Colorectal cancer cell lines (LoVo and HT-29)
Protein expression level depends on
the tumor size, lymph node metastasis,
other organ metastases, and tumor stage
[145]
Esophagus Gastric cancer patients
Gastric cell lines SGC-7901 and BGC-823
Increased protein levels associated with
lymph node metastasis and tumor stage
[136]
Cervix Normal smears from patients taking or not estrogens
Cervical cytologies from intraepithelial lesions
Biopsies from cervical intraepithelial neoplasias
Cervical cancer cell lines
Increased expression in high-grade
intraepithelial lesions
[30]
Brain Pilocytic astrocytoma (malignancy grade I)
Diffuse astrocytoma (malignancy grade II)
Oligodendroglial tumor (malignancy grade III)
Glioblastoma (malignancy grade IV)
Strong expression in normal brain
High expression in low-grade gliomas
Moderate expression in high-grade gliomas
[143]
EAG hEAG1 Blood Chronic myeloid leukemia (CML)
Acute myeloid leukemia (AML)
Up-regulation in all tested CML
Up-regulation in half of the tested AMLs
The expression correlates with increasing age,
higher relapse rates and a shorter overall
survival
[119]
hERG1 Colon Human colon cancer H630, HCT8, DLD1,
HCT116 cell lines
Human primary colorectal tumor samples
High gene and protein expression
in colon carcinoma cell lines
Increased expression of gene and protein
in metastatic primary human colorectal cancers
The protein amount and the channel activity
correlate with the invasion capacity of
cancer cells
[167]
Colon Colorectal cancer HCT116, HCT8, HT29 cell lines
Colorectal cancer mouse models
Induction angiogenesis and tumor progression
through interaction with β1-integrin
[178]
Esophagus Barrett's esophagus (BE) samples
Esophageal dysplasia (Ds) samples
Esophageal adenocarcinoma (ADKs) samples
Protein expression in 7% of patients
with BE lesions that does not proceed to cancer
Protein expression in 89% of patients
with BE lesions that progress toward ADKs
[195]
EAG hERG1 Stomach Human gastric cancer cell lines
SGC7901, AGS, MGC803, MKN45
Human immortalized gastric mucosa epithelial
GES cell line
Protein expression is associated with
differentiation and stage of gastric tumors
Protein silencing can decrease invasiveness
and tumorigenicity of gastric cancer cells
[170]
Brain Murine neuroblastoma 41A3cell line Regulation of neurite outgrowth
mediated by integrin interacion
[185]
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Table 1 (continued)
Family Channel Tissue Tumors/cancer cell lines Evidences Reference
Brain Pilocytic astrocytoma (malignancy grade I)
Diffuse astrocytoma (malignancy grade II)
Oligodendroglial tumor (malignancy grade III)
Glioblastoma (malignancy grade IV)
Strong expression in normal brain
High expression in low-grade gliomas
Moderate expression in high-grade gliomas
.
[143]
Brain Glioblastoma multiforme (GBM) samples
Glioblastoma cell lines
Channel overexpression
in the high-grade astrocytoma GBM
Promotion of neo-angiogenesis by induction
of VEGF secretion in glioblastoma cell lines
[153]
Blood Human leukemic preosteoclastic FLG 29.1 cell line Regulation of ﬁbronectin
adhesion by integrin interaction
[182]
EAG hERG1 Blood Primary acute myeloid leukemia (AML) blasts Regulation of cell migration and invasion
by interaction with VEGFR-1 and β1-integrins
Channel expression correlates with a
higher probability of relapse and shorter
survival
[180]
EAG hERG1 Blood Primary acute myeloid leukemia (AML) blasts Regulation of cell migration and invasion
by interaction with VEGFR-1 and β1-integrins
Channel expression correlates with a
higher probability of relapse and shorter
survival
[180]
Blood Leukemic cell lines and leukemic stem cells
Primary acute leukemic cells
Regulation of cell migration through the
interaction with the stromal cell-derived
factor-1 (SDF-1)
[183]
Blood Acute lymphoblastic leukemia (ALL) cell lines
Acute lymphoblastic leukemia (ALL) primary cultures
Bone marrow samples from children with B-cell
precursor ALL
Human cell engrafted NOD/SCID mice
ALL hERG1+ patients show a better prognosis
Mice engrafted with ALL cells
and treated with channel blockers show
reduced leukemic inﬁltration and higher
survival
[181]
Skin MDA-MB-435S melanoma cell line Regulation of cell proliferation and migration [176]
Thyroid gland Human aggressive anaplastic thyroid cancer cells Modulation of cell migration [184]
K2P TASK-3 Breast Non-invasive human breast MCF-7 cancer cell line
Invasive breast MDA-MB-231 cancer cell line
Increased mRNA and protein in MCF-7 cells [242]
K2P TREK-1 Prostate Benign prostatic hyperplasia
Human prostate cancer PCa cells
Prostate cancer PC3 cell line
Positive expression in PCa cells and PC3 cell line [275]
Ovary SKOV-3 and OVCAR-3 cell lines
Epithelial ovarian tumor specimens
Association between channel expression
and disease prognosis, stage and grade
[276]
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control kidneys, similar to what we observed for Kv1.3 expression [64].
We can conclude that the expression of Kv1.5 increases in many tumor
cells and that the correlation between the expression and the tumori-
genic state may be attributable to remodeling mechanisms.
1.2. Ether-à-go-go potassium channels
1.2.1. Human ether-a-go-go voltage-gated potassium channel 1 (hEAG1)
Ether-à-go-go voltage-gated potassium channels are named after the
phenotype of the Drosophila mutants that allowed their identiﬁcation
[105]. As Kv channels, ether-à-go-go voltage-gated K+ channel 1
(EAG1) channels, encoded by the EAG1 gene, are typically closed at
the resting potential of cells but open after membrane depolarization.
EAG1 channels typically show slowly activating and non-inactivating
K+ currents with a voltage-dependence and a delayed rectiﬁcation at
strongly depolarized voltages [105,106]. However, the most peculiar
electrophysiological property of EAG1 is that the speed of activation
depends very strongly on the membrane potential before the stimulus
[107–110]. EAG1 provides the hyperpolarization needed prior to
myoblast fusion [30,111]. When expressed in heterologous systems,
the biophysical properties of EAG1 channels depend on the cell cycle
stage of the cells [110,112,113].
Human EAG1 was initially described as a cell-cycle regulated
channel [112,114] that was involved in the oncogenic progression of
tumor cells [115–117] (Table 1). In fact, EAG1 was the ﬁrst voltage-
gated K+ channel to be associated with oncogenesis and tumor
developmen. The oncogenic properties of this channel were demon-
strated when EAG1-transfected cell lines acquired properties that
were similar to those of cancerous cells, including the loss of cell contactinhibition, growth in low serum concentrations and the formation of
aggressive tumors when injected into immune-depressed mice [29].
To date, many studies have demonstrated the role of EAG1 in the
growth of cancer cell lines and in vivo tumor models [8,118–121]. For
example, EAG1 gene silencing by siRNA leads to a signiﬁcant reduction
in tumor cell proliferation in vitro [29,121,122] and impairs tumor
growth in vivo [123]. The inhibition of the EAG1 channel function also
reduces the proliferation of tumor cells. Unfortunately, there are no
speciﬁc blockers for EAG1 channels. Imipramine and astemizole,
which are non-speciﬁc blockers of EAG1, inhibit this channel and
decrease the proliferation of tumor cell lines [124]. EAG1 is expressed
in lung cancer biopsies [125], and in mouse models, oral doses of
astemizole also reduce the progression of subcutaneous tumors and
the frequency of metastasis in lung carcinoma [118]. However, imipra-
mine and astemizole also block hERG channels, resulting in cardiac
risk [126]. Similarly, chemotherapeutic agents such as tamoxifen
[127], which is used in breast cancer treatment, and α1-adrenoceptors
antagonists [128], which are used to treat benign prostatic hyperplasia,
inhibit ERG channel activity. Conversely, EAG1 favors xenograft tumor
progression in immunodeﬁcientmice in vivo, and its overexpression in-
creases cell proliferation [129]. The speciﬁc inhibition of EAG1 with
monoclonal antibodies also inhibits tumor cell growth both in vitro
and in vivo [120].
EAG1 channels exhibit a very restricted distribution in healthy tissues;
they are mainly conﬁned to the central nervous system and expressed at
low levels in the endometrium, placenta, testis, pancreatic acini, adrenal
gland, mast cells, myoblasts, and tissue-associated macrophages [29,
111,123,126,130,131]. In contrast, several clinical tumors of diverse ori-
gins have high EAG1 levels. In fact, human EAG1 transcripts were ﬁrst
found in tumor cell lines with different tissues of origin [26]. To date,
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several primary tumors, including neuroblastomas [27,29]; melanomas
[44,132,133]; breast cancers [123,134]; colon [135], gastric [136], and cer-
vical carcinomas [28]; rhabdomyosarcomas [137] and others [17,
138–143]. Moreover, hEAG1 is aberrantly expressed at a signiﬁcantly
high frequency in different types of tumors and cancer cell lines [119,
123,144]. Because of their particular pattern expression and oncogenic
properties, EAG1 channels may represent a new diagnostic marker and
therapeutic target for several types of malignancies [29,30,110].
Interestingly, the expression of EAG1 is a poor prognostic marker in
some human cancers [129]. There is a correlation between EAG1
expression levels and tumor recurrence and reduced overall survival
in patients with head and neck squamous cell carcinoma (HNSCC)
[141], colorectal [135], gastric [136], cervical dysplasia [30], brain
[143] and, acute myeloid leukemia [119]. This association supports the
notion that EAG1 may represent a promising prognostic biomarker in
various cancers [145]. Human EAG1 is aberrantly expressed in HNSCC-
derived cell lines at frequencies that are very similar to those described
in other cancer cell lines and primary tumors [119,144]. The expression
of EAG1 increases slightly during HNSCC progression and it is more
frequently found in larger and more poorly differentiated tumors in pa-
tients with advanced disease stages and lymph nodemetastasis. In vitro
functional studies have proved that the presence of EAG1 promotes
HNSCC cell proliferation and invasion. Thus, aberrant EAG1 expression
may confer a proliferative advantage to and invasive potential tumor
cells, inducing tumors to grow faster and with increased aggressiveness
[141]. Agarwal and colleagues have detected EAG1 RNA in several leu-
kemic cell lines (K562, PLB-985, UT-7, HL-60 and HEL). Their functional
studies have also shown the potential of hEAG1 inhibitors to reduce
proliferation and migration of acute myeloid leukemia cell lines [119].
However, transcripts for the EAG channel were detected at low levels
in K562 (a chronic myelogenous leukemic cell line) and MOLT-4 (an
acute lymphoblastic leukemia line) in a previous study [146].
Kv channels control the proliferation of T84 colon cancer cells, and
the abnormal expression of Kv channels may serve as a useful marker
for malignant transformation. It is important to note that human biop-
sies of colorectal carcinomas and carcinogen-treated mice show high
levels of EAG1 in colon cancers, while this protein is not detected in
the healthy colon [147]. Moreover, the EAG1 gene is induced in tumor
specimens and is signiﬁcantly associated with reduced survival rate in
patients with colon carcinoma. Because EAG-1 is already expressed
during the premalignant stage, EAG-1 transcripts detected in rectal
biopsies are important for tumor development and may serve as an
early diagnostic and prognostic marker, as in cervical cancer. EAG1 is
functionally expressed in samples from cervical carcinoma patients
and absent from normal tissue [28]. Moreover, EAG1 is differentially
overexpressed in at-risk cervical cytologies compared to normal cervical
tissues and increases from low- to high-grade intraepithelial lesions.
Interestingly, estrogens regulate the expression of the EAG1 gene, and
almost half of healthy women that take estrogens display EAG1 expres-
sion. Thus, EAG1 may be a potential risk indicator for developing cervi-
cal lesions in patients taking estrogens. Human papilloma virus (HPV)
oncogenes, the most important etiological factors for cervical cancer,
also regulate the expression of EAG1. In addition, when keratinocytes
are immortalized with human papilloma virus oncogenes E6 and E7
they begin to transcribe EAG1 mRNA [148]. All these ﬁndings suggest
that EAG1 may be present in pre-malignant lesions, where it acts as
an early risk indicator of cervical dysplasia [30]. In addition to cervical
cancer [149], HPV infection has also emerged as a factor associated
with the development of colorectal [150], head andneck (which include
the oral cavity and oropharynx) [151] and urological cancers [152].
EAG1 transcripts have also been detected in human diverticulitis,
which has the potential to transform into colonic cancer. In this way,
EAG1 could function as a marker of adverse prognosis in some human
colorectal adenocarcinomas [135]. The EAG1 channel is also frequently
expressed in a large proportion of human soft tissue sarcomas andseveral sarcoma cell lines while being absent from healthy tissues.
Additionally, EAG1 is aberrantly expressed in many sarcomas, and the
inhibition of EAG1 expression and function reduces the proliferation
of several sarcoma cell lines [144]. The expression of EAG1 increases
both the metabolic activity and proliferation rate of Chinese hamster
ovary (CHO) cells. In an immunodeﬁcient mouse model, EAG1-
transfected CHO cells cause rapidly growing tumors, whereas wild
type CHO cells are much less aggressive. Thus, the expression of EAG1
confers a selective advantage to cancer cells [29,144]. Two interesting
exceptions to this effect are glioblastoma multiforme and malignant
brain tumors, where the levels of EAG1 channel are lower than those
of native brain tissue [143,153]. Although EAG channels are expressed
in normal brain tissue, it is important to note that gliomas exhibit a dif-
ferential expression of both hERG and EAG1 channels depending on the
malignancy grade and nature of the tumor cells. Thus, their expression
seems to be inversely related to the malignancy of the tumor [143].
Interestingly, astrocytes normally express EAG1, while in glioblastomas
there is a signiﬁcant downregulation of channel expression [143]. EAG1
K+ currents have been also recorded in the nuclear inner membrane in
human and rat models where they participate in setting nuclear [K+]
and indirectly interact with heterochromatin. Since these processes
affect gene expression, genome stability and cell senescence [154],
nuclear EAG1 may be also relevant to cancer [155].
The restricted distribution of EAG1 in normal tissues is one of the
most attractive features of EAG1 as a potential tumor marker. Efforts
to elucidate the mechanisms underlying this expression pattern have
been largely unsuccessful. However, it is generally accepted that the
expression of EAG1 may offer a selective advantage to tumor cells
through increased vascularization and resistance to hypoxia [118].
EAG1 expression also appears to also affect cytoskeletal organization,
which may inﬂuence proliferation, migration and metastasis [156].
EAG1 is also involved in cell adhesion processes ultimately leading to
tumor progression [156]. The main question is whether EAG1 expres-
sion in tumor cells is a consequence of the abnormal growth or if
these channels are necessary for cell proliferation [126]. To date, we
know that EAG1 induces malignant transformation in ﬁbroblasts,
while its expression is secondary to malignant transformation in colon
cancer cells [135,157]. Noticeably, ion permeation does not seem to be
necessary because some non-conducting mutants retain the ability to
modulate proliferation and tumorigenesis [118,158]. Because EAG1
chemical blockers and selective antibodies have limited applicability
to the treatment of head and neck cancers, the oncogenic role of EAG1
seems to be independent of its function as an ion channel [141]. Various
studies demonstrate a link between EAG1 expression and different
cancer risk factors, suggesting a role of this channel in the pathogenesis
the disease [159]. The expression of EAG1 can also be induced by treat-
mentwith chemical carcinogens inmousemodels of colon cancer [135].
Aberrant EAG1 expression has been detected in most head and neck
tumors, while no expression is found in normal epithelia from non-
oncologic patients. It remains to be determined whether EAG1 plays
an active role in malignant progression or is simply a consequence of
tumor development [141].
The idea of ion channels as therapeutic membrane targets has gar-
nered increasing attention. EAG channels are particularly attractive as
cancer targets because their surface expression is not detected in nor-
mal tissue outside the central nervous systembut is signiﬁcantly detect-
ed in many tumors of different origins. In addition, EAG transcripts are
aberrantly expressed in several human cancers, and the inhibition of
these channels impairs the proliferation of tumor cell lines. Therefore,
speciﬁc antibodies against EAG1 may represent promising tools for the
development of strategies that selectively kill tumor cells [160].
1.2.2. Human ether-à-gongo-related gene voltage-gated potassium channel
1 (hERG1)
Human ether-à-go-go related gene (hERG) K+ channel (also known
as Kv11.1 and encoded by KCNH2) is another voltage-gated K+ channel
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channels but exhibits biophysical features that distinguish it from other
members of this family, such as strong inward rectiﬁcation [26,161]. The
biophysical properties of this channel also include relatively fast kinetics
of the inactivation gate and much slower kinetics of the activation gate
[162]. hERG channels are mainly expressed in the heart, where they are
responsible for the IKr current and associate with minK proteins to
regulate the duration of the action potential repolarization [163]. In
contrast to EAG channels, hERG expression is ubiquitous in normal
human tissues. Therefore, hERG transcripts have also been found in
brain, kidneys, liver, pancreas, testes, uterus, prostate, hematopoietic
progenitors, and other tissues [15,164–166].
In human cancer, hERG was ﬁrst reported in neuroblastoma cells to
be responsible for resting-potential variations [27,115]. Since then,
several studies have identiﬁed hERG channels in many neoplastic cell
lines with different tissue origins [26] and in primary human cancers
[137,166,167]. In tumor cells, hERG channels have been reported to be
differentially expressed throughout the cell cycle. In fact, two described
isoforms of hERG coexist; hERG1b expression is prominent in the S phase
of the cell cycle, and hERG1a is more abundant in the G1 phase [137]. In
addition, hERG1 is often aberrantly expressed in tumor cell lines and
primary cancers, especially in early stages, where it frequently exerts
pleiotropic effects on the neoplastic cell physiology [168]. For instance,
hERG is found to be overexpressed in leukemia [146,166], gliomas
[153], colorectal [135,167] and endometrial cancers [165]. In general,
Kv channel overexpression is a recurrent feature of early cancer stages,
most likely because of the role of the channel in cell proliferation. Later
phases presentmore variability, perhaps due to the different physiolog-
ical needs of neoplastic cells derived from different tumors. Interesting-
ly, hERG expression has also been linked to higher grade and poorer
prognosis in several malignancies [146,165,167,169,170]. Thus, many
studies suggest that hERG channels may play a prominent role in the
control of cancer cell proliferation and tumor progression [7,27,29,
171] (Table 1). hERG1 blockage tends to inhibit cell proliferation in
many primary cultures and human cancer cell lines [13,88,146,166,
168,172–176]. Although the mechanism of this inhibition is unclear, it
is known that voltage-gated K+ channels differentially regulate the
resting voltage during proliferation [177]. In fact, hERG1 current can
contribute to driving the resting voltage of tumor cells to rather
depolarized values due to its biophysical properties [26,115,161,162].
In addition, hERG channels stimulate tumor neo-angiogenesis by the
secretion of vascular endothelial growth factor (VEGF) [153,178]. At
the same time, hERG channels physically interact with adhesion recep-
tors of the integrin family [179], growth factors [180] and chemokines
[181] to control cell migration, differentiation and proliferation. All
these processes may present a selective advantage to a number of
human cancers [26,153,167,176,182–184].
hERG channels are constitutively expressed in neuroblastoma [115,
185], where they contribute to control the membrane voltage potential
as well as neuronal excitability [186]. Moreover, a macromolecular
complex between β1 integrins and hERG channels regulates the
adhesion-dependent differentiation of neuroblastoma cells [187,188].
In gliomas, the differential expression of hERG1 and EAG1 mRNA
depends on the malignancy grade and nature of the tumor cells. Thus,
the expression of hEAG1 has been reported to be moderate in high-
grade gliomas and high in low-grade ones, especially control tissues
[143]. This downregulation of hERG in malignant gliomas seems to be
different from that of non-neural tumors [165]. Although it seems
quite surprising, similar lowexpression has been reported for the Shaker
subfamily of K+ channels [50], suggesting that this may be a general
hallmark of high-grade gliomas. In contrast, hERG1 is overexpressed
in the high-grade astrocytic tumor known as glioblastoma multiforme
(GBM) where it contributes to malignancy by promoting the secretion
of VEGF [153]. The discrepancy between these data may be due to the
experimental approach; Patt and co-workers tested mRNA expression
using whole brain tissue, which expresses hERG1 [189].In contrast, the expression of hERG1 turns out to be upregulated in
leukemia [146]. Interestingly, the expression of hERG channels is signif-
icantly correlated with a more aggressive phenotype in human acute
myeloid leukemia (AML) [180]. In AML cells, an interaction between
hERG1 and β1 integrin is associated with VEGF secretion and can regu-
late cell proliferation as well as migration and invasion. Physical and
functional interaction between hERG1 and integrins is twofold: integrin
activation depends on hERG1 channel activity because it is severely
impaired by speciﬁc hERG1 blockers. More than that, β1 integrin sub-
units can functionally activate hERG1 in leukemia cells [182] and neuro-
blastoma [185]. Once activated by integrins, hERG proteins modulate
adhesion signaling pathways downstream to integrin receptors [190].
The β1 subunit linked to hERG coassemble with caveolin-1 particularly
after integrin engagement to extracellular matrix. Then, activated hERG
induce the recruitment of focal adhesion kinase (FAK) and its subse-
quent phosphorylation and activation of Rac1 [187]. Likewise, K+
currents modulate FAK phosphorylation after cell adhesion to ﬁbronec-
tin in neuroblastoma cells [191]. In leukemia cells, hERG1–β1 integrin
macromolecular complexes trigger signaling pathways that determine
neoplastic progression and malignancy by recruiting growth factor
and chemokine receptors [180,192]. In addition, hERG1–integrin β1
complexes modulate phosphorylation of PI3K and VEGF-A secretion to
control tumor cell neoangiogenesis and progression of colorectal cancer
[178]. Acute lymphoblastic leukemia (ALL) cells that are co-cultured
with bone marrow mesenchymal cells express hERG1 either as single
proteins or complexed with integrins in lymphoblasts [193]. Similarly,
childhood B-acute lymphoblastic leukemia (BALL) cell lines as well as
primary BALL cells expresses functional hERG1–β1 integrin complexes
[194]. In pediatric ALL, the inhibition of hERG impedes bone marrow-
induced protection against chemotherapeutic drugs, restoring substan-
tial apoptotic cell death. Speciﬁc hERG1 blockers also exert anti-
leukemic activity, increasing the rate of cell apoptosis in bone marrow
and reducing the leukemic inﬁltration of peripheral organs in murine
models. In ALL cells, hERG inhibitors abrogate the protective effect of
bone marrow stromal cells on leukemic cells and enhance the cytotox-
icity of some common anti-leukemic drugs. Therefore, hERGmodulators
may overcome chemoresistance in acute leukemia, a major obstacle to
therapeutic success [181]. Although the cohort of the study may be
too small for the results to be conclusive, ALL hERG1+ patients undergo-
ing standard chemotherapy showed a higher probability of relapse, a
shorter time to relapse, lower rates of complete remission, and a shorter
overall survival compared to hERG1− patients [181]. The human leuke-
mic preosteoclastic cell line (FLG 29.1), which expresses hERG channels,
can also adhere to puriﬁed ﬁbronectin through integrin receptors.
Moreover, hERG current shows an early activation that is apparently
sustained by the β1 integrin subunit activation to control cell differenti-
ation [182]. Many tumor cells, especially in leukemia, express the
truncated isoform hERG1b along with the full length protein to form
heterotetrameric channels [168]. In addition, leukemia cells express
another truncated form of hERG1 protein that lacks most of the N-
terminus and generate functional currents [137].
Similar to leukemic murine models, treating nude mice with the
hERG blocker E4031 for two weeks after the subcutaneous injection of
human gastric cancer cells decreases tumor growth [88]. hERG is
expressed in gastric cancer cell lines and primary tumors [170], and
the hERG blocker cisapride inhibits the cell cycle [173]. Although a
high expression level of hERG is not restricted to gastric cancer cells, it
is responsible for the malignant phenotype of gastric cancer [173]. In
fact, different studies have identiﬁed the hERG channel as a potential
biomarker for gastric cancer invasion and survival [136,169]. Moreover,
hERG has been found in pre-cancerous lesions of the stomach and lower
esophageal tract and has a strong correlation with later progression
toward adenocarcinoma. Dysplasias (Ds) and adenocarcinomas
(ADKs) of the human esophagus show a high expression of hERG1
protein.Most patients with the premalignant lesion Barrett's esophagus
(BE) express hERG1, whereas normal samples from patients with
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port the hypothesis that hERG1 expression marks an early step in the
malignant progression of BE to adenocarcinoma [195]. It is important
to note that BE samples turned out to be negative for Ki67 expression,
while Ki67 positivity in Ds and ADKs was limited to sparse cells [195].
The hERG1 gene and hERG1 protein are also upregulated in colorectal
cancer cells and primary samples, but no expression is detected in
normal colonic mucosa. Because the highest expression of hERG1 is
detected in cancers with invasive and metastatic phenotypes, it is
generally accepted that the channel activity modulates colon cancer
malignancy. hERG channels may modulate the migration and invasion
of colon cancer cells [196] though a functional association with β1
integrin [182,185]. The activated signaling pathways mediate cell adhe-
sion to the ECM and promote the secretion of VEGF-A, which sustains
angiogenesis. In fact, blocking hERG1 inhibits angiogenesis, cell growth
and metastatic spread in colorectal cancer cells in vivo [178]. The link
between hERG1 expression and invasive capacity has been conﬁrmed
by experiments in HEK293 cells transfected with hERG1 [167]. More-
over, it is believed that in colorectal cancer, most Kv channels control
cell proliferation [147], whereas hERG appears to control invasiveness
in later stages by interactions with β1 integrins [187,188]. As with
EAG, hERG1 is detected in the colons of Apcmin/+mice that developmul-
tiple adenomas in the small intestine. In contrast, hERG1-transgenic
mice, which show the ubiquitous expression of hERG1, do not exhibit
any other speciﬁc phenotypes and have a normal life span. These data
demonstrate that the overexpression of hERG1 does not induce tumor
development per se, although it is relevant in the progression of
colorectal carcinogenesis [197]. hERG channels are frequently more
expressed in biopsies from endometrial cancer compared to non-
cancerous endometrium and are physically linked to β1 integrins to
modulate adhesion-dependent signaling in endometrial cancer [165].
hERG–KCNE complexes have also been detected in both squamous
and endometrial cancer cell lines [198]. In the human mammary
carcinoma cell line MCF-7, hERG most likely regulates cell volume and
not proliferation, as suggested by experiments utilizing speciﬁc inhibi-
tors [199]. In fact, the expression of hERG channels has been detected
in many human cancers, including pancreatic ductal adenocarcinoma
[200] and melanoma, where they control cell proliferation and
migration [176].
Current evidence demonstrates that hERG is a proliferation-related
gene that may provide a selective advantage to cancer cells [26]. There-
fore, hERG channels and their inhibitors could be used not only as novel
prognostic factors but also as novel molecular targets in the future.
Selective hERG channel blockers such as E4031, Sertindole, Erythromy-
cin, curcumin andDoxazosin provide direct evidence of a functional role
for the hERG current in cancer cells [126,201]. However, most hERG1
blockers represent the worst possible combination because they bind
the channel intracellularly and trigger serious side effects. Many drugs
inhibit hERG because of the structural features of the inner channel
cavity to which most of these drugs bind [202]. At the same time,
hERG blockers can cause fatal cardiac arrhythmias [201]. Noticeably,
there are at least three alternative transcripts or hERG that have differ-
ential expression in the heart and in tumor cells. This observation raises
the possibility of selectively inhibiting the channel in tumors while
preserving the function of the heart [137,203]. Interestingly, the
efﬁcient hERG blocker roscovitine does not induce arrhythmia, most
likely due to its low afﬁnity for the closed and inactivated states of the
channel [204]. As a matter of fact, pharmaceutical companies have
made great efforts to develop hERG-selective compounds.
1.3. Two pore-domain K+ channels
1.3.1. TWIK-related acid-sensitive potassium channel 3 (TASK-3)
TWIK-related acid-sensitive potassium channel 3 (TASK-3), also
known as K2P9.1, belongs to the family of two-pore domain (K2P) potas-
sium channels [205]. As its name indicates, K2P channels have uniquemembrane topologies consisting of two pore-forming regions ﬂanked
by four transmembrane domains [206]. Because K2P channels display
inward currents with little time and voltage dependence, they show
characteristics of a leak current carrying a background K+ conductance
and set the resting membrane potential [207–209]. Based on both
sequence homology and functional characteristics, the 15 known
human K2P channels are classiﬁed into six subgroups, wherein the
TWIK-related acid-sensitive K+ channels TASK-1 (KCNK3), TASK-3
(KCNK9), and TASK-5 (KCNK15) form one subgroup. Except for TASK-
5, which is not expressed functionally, the other two members (TASK-
1 and TASK-3) exert relevant effects on cell excitability [33,210–213]
and have been related to diverse human cancers.
TASK-3 channels generate outwardly rectifying currents that are
modulated by a wide range of chemical and physical stimuli such as
acidiﬁcation [206,214–216] and hypoxia [217]. TASK-3 activity is
blocked by external divalent cations such as Zn2+ and Ba2+ as well as
quinidine, lidocaine and ruthenium red [206,216]. On the other hand,
TASK-3 is stimulated by the volatile general anesthetic halothane
[218] but inhibited by the local anesthetic bupivacaine [219–221]. In
humans, the presence of TASK-3 is normally observed in the brain,
with particularly strong expression in the cerebellum [206,215], as
well as in the adrenal cortex, gastrointestinal tract, and salivary glands
[222,223]. Many studies have indicated that TASK-3 channels are in-
volved in a number of physiological functions, including the regulation
of aldosterone secretion [224,225] and the resting membrane potential
[209,226–228]. They also participate in the interactions between neu-
rons and glia [229] and mediate the sensitivity of peripheral chemore-
ceptors to hypoxia and pH [230,231]. In addition, several studies have
demonstrated the oncogenic potential of TASK-3 channels (Table 1).
First of all, the ampliﬁcation of the KCNK9 gene (which encodes the
TASK-3 protein) has been reported in a number of cancer entities such
as breast, prostate and lung cancers [31] as well as malignant melano-
mas [232]. Similarly, KCNK9 overexpression has been observed in ap-
proximately half of the colorectal carcinomas tested although the
protein level is not related to tumor stage [233]. The overexpression of
the KCNK9 gene promotes tumor formation and induces resistance to
both hypoxia and serum deprivation. The overexpression of KCNK9 in
NmuMG cells (a cell line derived from mammary epithelial tissue) and
NIH-3 T3 ﬁbroblasts does not result in their transformation, but mice
injected with NmuMG cells overexpressing TASK-3 develop tumors
[31]. Furthermore, wild-type KCNK9 confers a growth advantage to
cells, whereas the inactivating mutant has no effect on cell growth.
These results suggest that a functional ion channel is required for the
regulation of cell proliferation and the oncogenic properties of TASK-3
channels [234]. Thus, KCNK9 is an established proto-oncogene whose
ampliﬁcation causes a signiﬁcant tumorigenic effect promoting cell pro-
liferation [31]. However, it remains uncertain exactly howTASK-3 chan-
nels may exert tumorigenic properties. One possibility is that TASK-3
overexpression may favor the survival of tumor cells, increasing their
resistance to hypoxia and serum deprivation in the poorly oxygenated
areas of solid tumors [234]. In fact, the acid-base balance of tumor
cells appears to be universal for all solid tumors [235], and TASK-3 is
modulated by extracellular acidiﬁcation. The KCNK9 gene has also
been identiﬁed as a proto-oncogene thatmay provide selective pressure
for copy number increase at chromosome 8q24 [31], which has been
reported as a frequent event in several cancers [236].
TASK channels have been shown to play a key role in tumorigenesis
and apoptosis [33]. In cerebellar granule cells, TASK-3 channel activity
may trigger apoptosis [237],whereas under certain experimental condi-
tions, the presence and activity of TASK-3 can have the opposite effect,
providing protection from neuronal death [238]. Although it is not
clearwhy the activity of TASK-3may either induce or prevent apoptosis,
it seems to be important for tumorigenic functions in many cell types.
The transfection of TASK-3 in the C8 embryonic mouse ﬁbroblast cell
line increases its survival under pro-apoptotic conditions (low serum
conditions and hypoxia) by inhibiting intracellular apoptosis pathways
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expressing KCNK9 causes tumor development [234]. In contrast, C8
cells transfected with a mutated KCNK9 (G95E) that abolishes TASK-3
channel activity have reduced oncogenic properties including prolifera-
tion in serum deprivation, resistance to apoptosis and tumor cell
growth. However, the overexpression of wild-type KCNK9 results in a
signiﬁcant reduction of TNF-induced apoptosis. The introduction of a
dominant-negative TASK-3 subunit into the human lung carcinoma
cell line Ben, which overexpresses TASK-3, reduces cell proliferation.
These results directly link TASK-3 function and malignant transforma-
tions [234].
On the other hand, TASK-3 expression has been identiﬁed in normal
ovaries and in the SKOV-3 and OVCAR-3 ovarian cancer cell lines and
ovarian tumors. Increased immunostaining of TASK-3 confers a survival
advantage, whereas TASK-3 blockers cause signiﬁcant reductions in cell
proliferation and increases in apoptosis in SKOV-3 and OVCAR-3 cells.
Therefore, TASK-3 could prove to be both a novel tumor marker and a
new therapeutic target in ovarian cancer [239]. Benign melanocytes
and malignant melanoma cells also show TASK-3 channel expression.
However, one of the most surprising discoveries is the ﬁnding that the
TASK-3 protein seems to be localized intracellularly, mostly concentrat-
ed in the perinuclear region of healthymelanocytes andmelanoma cells
[240]. Similarly, TASK-3 channels are strongly located around the nucle-
us of colorectal cancer cells [223,232,233]. It is known that TASK-3
proteins are also present in themitochondrialmembranes ofmelanoma
cells andHaCaT keratinocytes, where theymay contribute tomitochon-
drial functions, although their role there remains elusive [87,232]. In
fact, different K+ channels have been shown to play a role in mitochon-
drial dysfunction [241]. Interestingly, the inhibition of TASK-3 biosyn-
thesis induces characteristic changes in cell morphology and reduces
the amount of DNA, metabolic activity and mitochondrial function of
melanoma cells. These ﬁndings indicate that TASK-3 expression and
function are indispensable for the proliferation and survival of melano-
ma cells. Different studies have demonstrated that the function of TASK-
3 is essential for maintaining cellular integrity and viability, possibly by
providing greater hypoxia tolerance through a still unknown mecha-
nism. TASK-3 may have clinical relevance because the inhibition of its
biosynthesis cause mitochondrial dysfunction leading to the damage
and eventual death of melanoma cells [240].
TASK-3 mRNA and protein are highly expressed in MCF-7 cells, a
non-invasive human breast cancer cell line, compared with MDA-MB-
231 cells, an invasive breast cancer cell line. Interestingly, the overex-
pression of TASK-3, which can bemodulated by PKC activation, reduces
migration and invasion in breast cancer cells, whereas its silencing
increases both parameters. These results suggest that the modulation
of TASK-3 expression may regulate metastasis in breast cancer cells
[242]. In Ehrlich ascites tumor cells, cell swelling-activated K+ currents
show biophysical properties and pharmacological proﬁles that are
similar to those described for TASK channels [243]. Furthermore, two
human glioma cell lines (U373, LN319) as well as glioma specimens
constitutively express TASK-1 and TASK-3 mRNA and protein. In addi-
tion, a TASK channel activator [220,244] induces cell death in different
human glioma cell lines. This effect could be prevented by the TASK-1
and TASK-3 channel inhibitor bupivacaine [209] and by spermine,
which inhibits TASK-3 channels [245], but not by the TASK-1-speciﬁc
modulator anandamide [208,246]. These data indicate a clear link
between TASK-3 function and cell death in human glioma cells. The
chemo-sensitive properties of TASK-3, such as pH and hypoxia depen-
dency,may be especially relevant in the hypoxic and acidicmicromilieu
that often occurs in the center of a solid tumor [33]. However, the
expression of TASK-1 and TASK-3 in normal brain tissues indicates
that pharmacological intervention through TASK must be undertaken
with caution. A signiﬁcant reduction in cell proliferation has been
conﬁrmed with TASK-3 blockers, but unfortunately, there are no
known speciﬁc K2P channel blockers, and these drugs exhibit other
actions in addition to the blockade of TASKs [222].Thus, TASK-3 channels promote the survival of cancer cells under
certain conditions [238], whereas in other cases, their presence and
activity induce apoptotic cell death [247,248]. There are several hypoth-
esis trying to explain this paradoxical phenomenon [8,33]. Although the
exact link between TASK activity and apoptosis is still unclear, TASK-1
and TASK-3 subunits seem to be essential for the induction of apoptosis
in cerebellar granule cells. This effect requires the channel activity
because the loss-of-function mutants do not alter cell viability [237].
When TASK-3 is active at the cell surface, its activation causes the efﬂux
of K+. This fact, accompanied by the outﬂow of Cl− and an osmotic
water loss, leads to apoptotic volume decrease, which is a key initiator
of the apoptotic process. At the same time, the reduction in the intracel-
lular K+ concentration acts as an important regulator of the nucleases
and caspases that play prominent roles in apoptosis [249–251]. In
contrast, when TASK is located in the mitochondria (in melanoma and
keratinocytes), its activity may contribute to the maintenance of mito-
chondrial functions and provides energy supply to healthy and malig-
nant cells to promote their survival.
1.3.2. TWIK-related acid-sensitive potassium channel 1 (TASK-1)
Outward rectiﬁcation currents mediated by TASK-1 (K2P3.1) are
sensitive to variations in the extracellular pH [214] and blocked by the
local anesthetic bupivacaine [252] and opened by halothane and
isoﬂurane [221,253]. As in TASK-3 channels, TASK-1 activity is blocked
by Ba2+ and Zn2+. TASK-1 protein is found in the brain, with a particu-
larly strong expression in the cerebellum [254,255]. Endogenous TASK-
1-like currents have been recorded in rat heart myocytes [256] and rat
type-I carotid body cells [217]. Additionally, TASK-1 is expressed in
the lungs, the pancreas and the placenta [214,257]. Noticeably, both
TASK-1 and TASK-3 can form functional heterodimers [258–260] that
may contribute to cell death in cerebellar granule neurons [237]. Similar
to TASK-2 and TASK-3, the overexpression of TASK-1 enhances the
viability of transfected C8 cells by inhibiting intracellular apoptosis
pathways [238]. The differential expression of TASK-1 can also be corre-
lated with the prolonged survival of patients with advanced colorectal
cancer [261]. Because of this association, TASK-1 may be considered as
a new prognostic marker for colonic cancer.
1.3.3. TWIK-related K+ channel-1 (TREK-1)
Another subgroup of K2P channels includes three members: TWIK-
related K+ channel-1 (TREK-1, encoded by KCNK2), TREK-2 (KCNK10)
and TWIK-related, arachidonic acid-stimulated K+ channel (TRAAK,
KCNK4). Among them, TREK-1 channels are the ones related to different
cancer entities [262,263]. TREK-1 is found in the brain with a speciﬁc
and strong expression in the striatum [254,264]. Its outward rectifying
currents are time- and voltage-independent and modulated by cell
volume [265], temperature [266] and intracellular acidosis [267].
TREK-1 is opened by volatile anesthetics [221], polyunsaturated fatty
acids [268] and mechanical stretching [265] and inhibited by external
Mg2+ at negative potentials [269,270], amiloride, Gd3+ [265], Ca2+
antagonists [271] and the KATP channel blocker glibenclamide [272].
Similar to TASK channels, a functional TREK-1 is present in the plas-
mamembrane, but a substantial proportion of TREK-1 protein is also lo-
calized to the nucleus. This unexpected TREK-1 population could not
contribute to the regulation of either plasma membrane potential or
cell volume. In fact, TREK-1 channels have been associated with differ-
ent oncogenic functions (Table 1). Wild-type TREK-1 does not induce
cell death, but the constitutively active mutant E306A [273] mimics
the effect of TASK channels and induces neuronal cell death [237]. In ad-
dition, the anti-apoptotic role for TREK-1 has been shown using riluzole
red, a nonspeciﬁc TREK-1 activator that prevents cell death aswell as is-
chemic spinal cord injury [274]. Like TASK-3, the oncogenic ability of
TREK-1 may depend on its activity as an ion channel. Thus, non-
functional channels not only lose their tumorigenic capability but can
act as dominant negative mutants, blocking the endogenous channel
function and preventing the formation of tumors [234].
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[275] as well as the PC3 prostate cancer cell line. However, neither
normal prostate epithelium (NPE) nor benign prostatic hyperplasia
expresses detectable levels of TREK-1. Moreover, the overexpression
of TREK-1 increases the proliferation rate of both NPE and Chinese
hamster ovary (CHO) cells, conﬁrming the importance of this channel
in the regulation of cell growth. Conversely, the inhibition of TREK-1
activity in cultured cancer cells by a nonspeciﬁc blocker or by a
dominant-negative mutant of the channel reduces proliferation to
near-normal levels. All these data suggest that the expression of TREK-
1 is associated with abnormal cell proliferation and may be a prostate
tumor marker and a novel therapeutic target [262].
Both TREK-1 and TREK-2 channels are expressed in SKOV-3 and
OVCAR-3 ovary cell lines, normal ovaries and epithelial ovarian tumors.
Interestingly, the proliferation of SKOV-3 and OVCAR-3 cells is reduced
by TREK-1-modulating agents. Curcumin, which inhibits TREK-1, causes
a signiﬁcant reduction in early apoptosis and a signiﬁcant increase in
late apoptosis in SKOV-3 and OVCAR-3 cells. Immunohistochemical anal-
yses demonstrate associations between TREK-1 expression and disease
prognosis, stage, and grade [276]. The expression of TREK-1, TREK-2,
and TASK3 in the non-invasiveMCF-7 breast cancer cell line is signiﬁcant-
ly higher than in MDA-MB-231 cells. However, in contrast to TASK-3, the
overexpression of TREK-1, TREK-2, and TRAAK channels has no signiﬁcant
effect on the migration of invasive breast cancer cells [242].
1.4. Potential mechanisms involving K+ channels on tumor progression
The mechanisms by which K+ channels regulate cell proliferation
and apoptosis remain elusive [171,277]. Potassium channel activity
maymodulate cell growth through intracellular calcium signaling path-
ways by controlling the cell membrane potential [278,279]. In fact,
tumor cells tend to bemore depolarized than their normal counterparts
[280]. K+ channels would provide the driving force required for the
Ca2+ inﬂux that is necessary for cell cycle progression [134]. At the
same time, they may be involved in G1/S hyperpolarization, avoiding
a loss of intracellular K+ and preventing the cells from entering the
apoptotic pathway. In addition to changes in Ca2+ homeostasis, apopto-
sis is characterized by voltagemembrane decay and cell shrinkage [281,
282], both of which are related to the activity of K+ channels [129].
However, the mechanistic link between the activity of K+ channels
and cell proliferation control is much more complex. Alternatively,
EAG and hERG expressed on cancer cells, contribute to tumor angiogen-
esis [178] and cell migration [180] by controlling VEGF secretion and
interaction with integrin receptors, respectively. To complicate the
matter further, recent evidence suggests that the heterogeneousK+ currents
K+ ch
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Fig. 2. Potassium channels are involved in tumor progression through both permeation-related
driving force for Ca2+, as well as cell volume regulation. These changes can have substantial ef
processes, together with hypoxia response, inﬂuence angiogenesis, cell growth and invasion to
nels rely on protein-protein interactions regulating cell cycle and, as a consequence, tumor protumor microenvironment plays a signiﬁcant role in tumorigenesis
[283]. There is strong evidence that K+ channels are involved in physi-
ological processes related to cancer malignancy but it is currently difﬁ-
cult to assign a speciﬁc role for each channel in proliferation and
invasion of tumor cells. The main mechanisms involved in malignancy
are tumor growth, neoangionesis and metastatic spread (Fig. 2). It is
well established that cell migration can be inﬂuenced by Kv1.3, Kv1.5,
EAG1 and hERG1 channels, and therefore its speciﬁc inhibition it is pre-
dicted to reduce metastatic potential. In accordance with that, Kv1.5
gene silencing alters B-lymphocyte migration [79]. Similarly, the inhibi-
tion of EAG channel reduces the migration of acute myeloid leukemia
[119] and breast cancer cells [284] whereas hERG1 has been related to
the migration of leukemia [180], melanoma [176], and thyroid [184]
tumor cells. Interestingly, mice treated with the hERG1 inhibitor
E4031 do not show macroscopic tumor masses or liver metastases
contrary to controls [178]. The involvement of K+ channels in cell adhe-
sion signaling has beenmost clearly shown for hERG1 proteinwhich in-
teracts physicallywithβ1 integrin [187]. In amurinemodel of colorectal
cancer, hERG1–β1 integrin complexes regulate tumor angiogenesis by
the secretion of VEGF-A. On the other hand, speciﬁc processes causing
up- or down-regulation of K+ channels in human cancers are far from
being understood. Epigenetic mechanisms such as DNA methylation
have been implicated in the altered expression of Kv1.3 in pancreatic
cancer cells [285] and breast cancer cells [70] and it may explain
HERG1 changes in ovarian cancer cells [286]. Another evidence supports
that changes in histone acetylation are involved in aberrant expression
of EAG1 in head and neck cancer [141].
Potassium channels have been assigned a deﬁnitive place in tumor
biology, and their precise roles in carcinogenesis are not yet fully
clariﬁed. Because the expression of different K+ channels has been
reported to be altered in a number of human cancers and, in some
cases, correlates with tumor malignancy, the expression of a speciﬁc
combination of ion channels could be useful in tumor characterization.
In addition, increasing evidence supports the fact that different drugs
and toxins that block the activity of K+ channels decrease neoplastic
proliferation. Consequently, ion channels have been extensively
proposed as new and exciting targets for cancer therapy. Toxins isolated
from venomous animals such as margatoxin and stichodactyla
helianthus (ShK) are selective blockers for Kv1.3 but many other K+
channel inhibitors are nonspeciﬁc although they reduce cancer cells
proliferation. The use of the antihistamine astemizole and the antide-
pressant imipramine leads to a reduction in proliferation of breast
cancer cells [134] and melanoma cells [133], respectively. Both are
efﬁcient but rather nonspeciﬁc EAGI blockers [124]. The inhibition of
EAG could be accomplished more speciﬁcally using RNA interferenceannels
Cell cycle progression
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and non-conductingmechanisms. The former include changes inmembrane potential and
fects on processes like adhesion, migration, apoptosis, and cell-cycle progression. All these
control tumor progression. On the other hand, the non-canonical mechanisms of K+ chan-
gression.
2487N. Comes et al. / Biochimica et Biophysica Acta 1848 (2015) 2477–2492or functional anti-EAG1 antibodies. In fact, speciﬁc inhibition of EAG1
expression by antisense technology [29], siRNA [121] and speciﬁc block-
age of EAG1 with monoclonal antibodies inhibits tumor cell growth
both in vitro and in vivo [120]. Unfortunately, small molecule inhibitors
of EAG1 lead to the undesired HERG block. Thus, the design and charac-
terization of new compounds that speciﬁcally target K+ channelswould
be valuable tools to elucidate their physiological and pathophysiological
function. The use of K+ channels inhibitors in vivo has been excluded so
far becausemany of them are expressed in both tumor cells and healthy
cells. Therefore, it may be necessary to fully understand the speciﬁc
regulation of ion channels in tumor cells in order to consider them as
promising therapeutic targets for cancer.Acknowledgments
The work carried out by the Molecular Physiology Laboratory was
funded by Ministerio de Economia y Competitividad (Spain) grants
from the BFU (BFU2014-54928-R) and CONSOLIDER (CSD2008-00005)
programs. The editorial assistance of the American Journal Experts is
also acknowledged. The Molecular Physiology Laboratory would like to
acknowledge all past members who have contributed to this research.References
[1] B. Hille, Ion Channels of Excitable Membranes, 3rd ed. Sinauer, Sunderland, Mass,
2001.
[2] Z.A. McCrossan, G.W. Abbott, The MinK-related peptides, Neuropharmacology 47
(2004) 787–821.
[3] B.A. Niemeyer, L. Mery, C. Zawar, A. Suckow, F. Monje, L.A. Pardo, W. Stuhmer, V.
Flockerzi, M. Hoth, Ion channels in health and disease. 83rd Boehringer Ingelheim
Fonds International Titisee Conference, EMBO Rep. 2 (2001) 568–573.
[4] S.M. O'Grady, S.Y. Lee, Molecular diversity and function of voltage-gated (Kv) po-
tassium channels in epithelial cells, Int. J. Biochem. Cell Biol. 37 (2005) 1578–1594.
[5] T.E. DeCoursey, K.G. Chandy, S. Gupta, M.D. Cahalan, Voltage-gated K+ channels in
human T lymphocytes: a role in mitogenesis? Nature 307 (1984) 465–468.
[6] C.C. Shieh, M. Coghlan, J.P. Sullivan, M. Gopalakrishnan, Potassium channels: mo-
lecular defects, diseases, and therapeutic opportunities, Pharmacol. Rev. 52
(2000) 557–594.
[7] H. Wang, Y. Zhang, L. Cao, H. Han, J. Wang, B. Yang, S. Nattel, Z. Wang, HERG K+
channel, a regulator of tumor cell apoptosis and proliferation, Cancer Res. 62
(2002) 4843–4848.
[8] Z. Wang, Roles of K+ channels in regulating tumour cell proliferation and apopto-
sis, Pﬂugers Arch. 448 (2004) 274–286.
[9] L.A. Pardo, Voltage-gated potassium channels in cell proliferation, Physiology (Be-
thesda) 19 (2004) 285–292.
[10] K. Kunzelmann, Ion channels and cancer, J. Membr. Biol. 205 (2005) 159–173.
[11] M. Lan, Y. Shi, Z. Han, Z. Hao, Y. Pan, N. Liu, C. Guo, L. Hong, J. Wang, T. Qiao, D. Fan,
Expression of delayed rectiﬁer potassium channels and their possible roles in pro-
liferation of human gastric cancer cells, Cancer Biol. Ther. 4 (2005) 1342–1347.
[12] W. Zhanping, P. Xiaoyu, C. Na,W. Shenglan, W. Bo, Voltage-gated K+ channels are
associated with cell proliferation and cell cycle of ovarian cancer cell, Gynecol.
Oncol. 104 (2007) 455–460.
[13] S.H. Jang, S.Y. Choi, P.D. Ryu, S.Y. Lee, Anti-proliferative effect of Kv1.3 blockers in
A549 human lung adenocarcinoma in vitro and in vivo, Eur. J. Pharmacol. 651
(2011) 26–32.
[14] W.F. Wonderlin, J.S. Strobl, Potassium channels, proliferation and G1 progression, J.
Membr. Biol. 154 (1996) 91–107.
[15] J. Camacho, Ether a go-go potassium channels and cancer, Cancer Lett. 233 (2006)
1–9.
[16] M. Conti, Targeting K+ channels for cancer therapy, J. Exp. Ther. Oncol. 4 (2004)
161–166.
[17] L.A. Pardo, C. Contreras-Jurado, M. Zientkowska, F. Alves, W. Stuhmer, Role of
voltage-gated potassium channels in cancer, J. Membr. Biol. 205 (2005) 115–124.
[18] F.M. Ashcroft, From molecule to malady, Nature 440 (2006) 440–447.
[19] N. Villalonga, J.C. Ferreres, J.M. Argiles, E. Condom, A. Felipe, Potassium channels
are a new target ﬁeld in anticancer drug design, Recent Pat. Anticancer Drug
Discov. 2 (2007) 212–223.
[20] J.Y. Le Guennec, H. Ouadid-Ahidouch, O. Soriani, P. Besson, A. Ahidouch, C. Vandier,
Voltage-gated ion channels, new targets in anti-cancer research, Recent Pat. Anti-
cancer Drug Discov. 2 (2007) 189–202.
[21] W. Stuhmer, F. Alves, F. Hartung, M. Zientkowska, L.A. Pardo, Potassium channels
as tumour markers, FEBS Lett. 580 (2006) 2850–2852.
[22] A. Felipe, R. Vicente, N. Villalonga, M. Roura-Ferrer, R. Martinez-Marmol, L. Sole, J.C.
Ferreres, E. Condom, Potassium channels: new targets in cancer therapy, Cancer
Detect. Prev. 30 (2006) 375–385.
[23] M. Abdul, N. Hoosein, Expression and activity of potassium ion channels in human
prostate cancer, Cancer Lett. 186 (2002) 99–105.[24] M. Abdul, N. Hoosein, Voltage-gated potassium ion channels in colon cancer,
Oncol. Rep. 9 (2002) 961–964.
[25] K.W. Chang, T.C. Yuan, K.P. Fang, F.S. Yang, C.J. Liu, C.S. Chang, S.C. Lin, The increase
of voltage-gated potassium channel Kv3.4 mRNA expression in oral squamous cell
carcinoma, J. Oral Pathol. Med. 32 (2003) 606–611.
[26] L. Bianchi, B.Wible, A. Arcangeli, M. Taglialatela, F. Morra, P. Castaldo, O. Crociani, B.
Rosati, L. Faravelli, M. Olivotto, E. Wanke, herg encodes a K+ current highly con-
served in tumors of different histogenesis: a selective advantage for cancer cells?
Cancer Res. 58 (1998) 815–822.
[27] R. Meyer, S.H. Heinemann, Characterization of an eag-like potassium channel in
human neuroblastoma cells, J. Physiol. 508 (Pt 1) (1998) 49–56.
[28] L.M. Farias, D.B. Ocana, L. Diaz, F. Larrea, E. Avila-Chavez, A. Cadena, L.M. Hinojosa,
G. Lara, L.A. Villanueva, C. Vargas, E. Hernandez-Gallegos, I. Camacho-Arroyo, A.
Duenas-Gonzalez, E. Perez-Cardenas, L.A. Pardo, A. Morales, L. Taja-Chayeb, J.
Escamilla, C. Sanchez-Pena, J. Camacho, Ether a go-go potassium channels as
human cervical cancer markers, Cancer Res. 64 (2004) 6996–7001.
[29] L.A. Pardo, D. del Camino, A. Sanchez, F. Alves, A. Bruggemann, S. Beckh, W.
Stuhmer, Oncogenic potential of EAG K(+) channels, EMBO J. 18 (1999)
5540–5547.
[30] C.S. Ortiz, D. Montante-Montes, M. Saqui-Salces, L.M. Hinojosa, A. Gamboa-
Dominguez, E. Hernandez-Gallegos, B. Martinez-Benitez, M. Del Rosario Solis-
Pancoatl, E. Garcia-Villa, A. Ramirez, R. Aguilar-Guadarrama, P. Gariglio, L.A.
Pardo, W. Stuhmer, J. Camacho, Eag1 potassium channels as markers of cervical
dysplasia, Oncol. Rep. 26 (2011) 1377–1383.
[31] D. Mu, L. Chen, X. Zhang, L.H. See, C.M. Koch, C. Yen, J.J. Tong, L. Spiegel, K.C.
Nguyen, A. Servoss, Y. Peng, L. Pei, J.R. Marks, S. Lowe, T. Hoey, L.Y. Jan, W.R.
McCombie, M.H. Wigler, S. Powers, Genomic ampliﬁcation and oncogenic
properties of the KCNK9 potassium channel gene, Cancer Cell 3 (2003)
297–302.
[32] S. Bittner, T. Budde, H. Wiendl, S.G. Meuth, From the background to the spotlight:
TASK channels in pathological conditions, Brain Pathol. 20 (2010) 999–1009.
[33] A.J. Patel, M. Lazdunski, The 2P-domain K+ channels: role in apoptosis and tumor-
igenesis, Pﬂugers Arch. 448 (2004) 261–273.
[34] H. Lallet-Daher, M. Roudbaraki, A. Bavencoffe, P. Mariot, F. Gackiere, G. Bidaux, R.
Urbain, P. Gosset, P. Delcourt, L. Fleurisse, C. Slomianny, E. Dewailly, B. Mauroy,
J.L. Bonnal, R. Skryma, N. Prevarskaya, Intermediate-conductance Ca2+-activated
K+ channels (IKCa1) regulate human prostate cancer cell proliferation through
a close control of calcium entry, Oncogene 28 (2009) 1792–1806.
[35] Z.H. Wang, B. Shen, H.L. Yao, Y.C. Jia, J. Ren, Y.J. Feng, Y.Z. Wang, Blockage of
intermediate-conductance-Ca(2+)-activated K(+) channels inhibits progression
of human endometrial cancer, Oncogene 26 (2007) 5107–5114.
[36] X.W. Yang, J.W. Liu, R.C. Zhang, Q. Yin, W.Z. Shen, J.L. Yi, Inhibitory effects of block-
age of intermediate conductance Ca(2+)-activated K (+) channels on prolifera-
tion of hepatocellular carcinoma cells, J. Huazhong Univ. Sci. Technol. Med. Sci.
33 (2013) 86–89.
[37] H. Jager, T. Dreker, A. Buck, K. Giehl, T. Gress, S. Grissmer, Blockage of intermediate-
conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell
growth in vitro, Mol. Pharmacol. 65 (2004) 630–638.
[38] S. Amigorena, D. Choquet, J.L. Teillaud, H. Korn, W.H. Fridman, Ion channel blockers
inhibit B cell activation at a precise stage of the G1 phase of the cell cycle. Possible
involvement of K+ channels, J. Immunol. 144 (1990) 2038–2045.
[39] M.L. Day, S.J. Pickering, M.H. Johnson, D.I. Cook, Cell-cycle control of a large-
conductance K+ channel in mouse early embryos, Nature 365 (1993)
560–562.
[40] S.A. Kotecha, L.C. Schlichter, A Kv1.5 to Kv1.3 switch in endogenous hippocampal
microglia and a role in proliferation, J. Neurosci. 19 (1999) 10680–10693.
[41] R. Chittajallu, Y. Chen,H.Wang, X. Yuan, C.A. Ghiani, T. Heckman, C.J.McBain, V. Gallo,
Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their
role in G1/S phase progression of the cell cycle, Proc. Natl. Acad. Sci. U. S. A. 99
(2002) 2350–2355.
[42] R. Vicente, A. Escalada, M. Coma, G. Fuster, E. Sanchez-Tillo, C. Lopez-Iglesias, C.
Soler, C. Solsona, A. Celada, A. Felipe, Differential voltage-dependent K+ channel
responses during proliferation and activation in macrophages, J. Biol. Chem. 278
(2003) 46307–46320.
[43] N. Villalonga, R. Martinez-Marmol, M. Roura-Ferrer, M. David, C. Valenzuela, C.
Soler, A. Felipe, Cell cycle-dependent expression of Kv1.5 is involved in myoblast
proliferation, Biochim. Biophys. Acta 1783 (2008) 728–736.
[44] B. Nilius,W.Wohlrab, Potassium channels and regulation of proliferation of human
melanoma cells, J. Physiol. 445 (1992) 537–548.
[45] J.S. Strobl, W.F. Wonderlin, D.C. Flynn, Mitogenic signal transduction in human
breast cancer cells, Gen. Pharmacol. 26 (1995) 1643–1649.
[46] V. Rybalchenko, N. Prevarskaya, F. Van Coppenolle, G. Legrand, L. Lemonnier, X.
Le Bourhis, R. Skryma, Verapamil inhibits proliferation of LNCaP human pros-
tate cancer cells inﬂuencing K+ channel gating, Mol. Pharmacol. 59 (2001)
1376–1387.
[47] M. Abdul, A. Santo, N. Hoosein, Activity of potassium channel-blockers in breast
cancer, Anticancer Res. 23 (2003) 3347–3351.
[48] Q. Zhou, H.Y. Kwan, H.C. Chan, J.L. Jiang, S.C. Tam, X. Yao, Blockage of voltage-gated
K+ channels inhibits adhesion and proliferation of hepatocarcinoma cells, Int. J.
Mol. Med. 11 (2003) 261–266.
[49] T. Utermark, A. Alekov, H. Lerche, V. Abramowski, M. Giovannini, C.O. Hanemann,
Quinidine impairs proliferation of neuroﬁbromatosis type 2-deﬁcient human ma-
lignant mesothelioma cells, Cancer 97 (2003) 1955–1962.
[50] K. Preussat, C. Beetz, M. Schrey, R. Kraft, S. Wolﬂ, R. Kalff, S. Patt, Expression of
voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas, Neurosci.
Lett. 346 (2003) 33–36.
2488 N. Comes et al. / Biochimica et Biophysica Acta 1848 (2015) 2477–2492[51] H.Wulff, H.G. Knaus, M. Pennington, K.G. Chandy, K+ channel expression during B
cell differentiation: implications for immunomodulation and autoimmunity, J.
Immunol. 173 (2004) 776–786.
[52] W. Stuhmer, J.P. Ruppersberg, K.H. Schroter, B. Sakmann, M. Stocker, K.P. Giese, A.
Perschke, A. Baumann, O. Pongs, Molecular basis of functional diversity of voltage-
gated potassium channels in mammalian brain, EMBO J. 8 (1989) 3235–3244.
[53] M. Grunnet, H.B. Rasmussen, A. Hay-Schmidt, D.A. Klaerke, The voltage-gated po-
tassium channel subunit, Kv1.3, is expressed in epithelia, Biochim. Biophys. Acta
1616 (2003) 85–94.
[54] R. Swanson, J. Marshall, J.S. Smith, J.B. Williams, M.B. Boyle, K. Folander, C.J. Luneau,
J. Antanavage, C. Oliva, S.A. Buhrow, et al., Cloning and expression of cDNA and ge-
nomic clones encoding three delayed rectiﬁer potassium channels in rat brain,
Neuron 4 (1990) 929–939.
[55] J. Bielanska, J. Hernandez-Losa, T. Moline, R. Somoza, S. Ramon y Cajal, E. Condom,
J.C. Ferreres, A. Felipe, Differential expression of Kv1.3 and Kv1.5 voltage-
dependent K+ channels in human skeletal muscle sarcomas, Cancer Investig. 30
(2012) 203–208.
[56] Z. Varga, P. Hajdu, G. Panyi, Ion channels in T lymphocytes: an update on facts,
mechanisms and therapeutic targeting in autoimmune diseases, Immunol. Lett.
130 (2010) 19–25.
[57] G. Panyi, G. Vamosi, Z. Bacso, M. Bagdany, A. Bodnar, Z. Varga, R. Gaspar, L. Matyus,
S. Damjanovich, Kv1.3 potassium channels are localized in the immunological syn-
apse formed between cytotoxic and target cells, Proc. Natl. Acad. Sci. U. S. A. 101
(2004) 1285–1290.
[58] H. Wulff, C. Beeton, K.G. Chandy, Potassium channels as therapeutic targets for au-
toimmune disorders, Curr. Opin. Drug Discov. Dev. 6 (2003) 640–647.
[59] C. Beeton, M.W. Pennington, H. Wulff, S. Singh, D. Nugent, G. Crossley, I. Khaytin,
P.A. Calabresi, C.Y. Chen, G.A. Gutman, K.G. Chandy, Targeting effector memory T
cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoim-
mune diseases, Mol. Pharmacol. 67 (2005) 1369–1381.
[60] I. Szabo, J. Bock, A. Jekle, M. Soddemann, C. Adams, F. Lang, M. Zoratti, E. Gulbins, A
novel potassium channel in lymphocyte mitochondria, J. Biol. Chem. 280 (2005)
12790–12798.
[61] I. Szabo, J. Bock, H. Grassme, M. Soddemann, B. Wilker, F. Lang, M. Zoratti, E.
Gulbins, Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis
in lymphocytes, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 14861–14866.
[62] J. Xu, P. Wang, Y. Li, G. Li, L.K. Kaczmarek, Y. Wu, P.A. Koni, R.A. Flavell, G.V. Desir,
The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity,
Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3112–3117.
[63] J. Xu, P.A. Koni, P. Wang, G. Li, L. Kaczmarek, Y.Wu, Y. Li, R.A. Flavell, G.V. Desir, The
voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body
weight, Hum. Mol. Genet. 12 (2003) 551–559.
[64] J. Bielanska, J. Hernandez-Losa, M. Perez-Verdaguer, T. Moline, R. Somoza,
Y.C.S. Ramon, E. Condom, J.C. Ferreres, A. Felipe, Voltage-dependent potassium
channels Kv1.3 and Kv1.5 in human cancer, Curr. Cancer Drug Targets 9
(2009) 904–914.
[65] A. Felipe, J. Bielanska, N. Comes, A. Vallejo, S. Roig, Y.C.S. Ramon, E. Condom, J.
Hernandez-Losa, J.C. Ferreres, Targeting the voltage-dependent K(+) channels
Kv1.3 and Kv1.5 as tumor biomarkers for cancer detection and prevention, Curr.
Med. Chem. 19 (2012) 661–674.
[66] N. Comes, J. Bielanska, A. Vallejo-Gracia, A. Serrano-Albarras, L. Marruecos, D.
Gomez, C. Soler, E. Condom, Y.C.S. Ramon, J. Hernandez-Losa, J.C. Ferreres, A.
Felipe, The voltage-dependent K channels Kv1.3 and Kv1.5 in human cancer,
Front. Physiol. 4 (2013) 283.
[67] M. Abdul, N. Hoosein, Reduced Kv1.3 potassium channel expression in human
prostate cancer, J. Membr. Biol. 214 (2006) 99–102.
[68] S.P. Fraser, J.A. Grimes, M.B. Djamgoz, Effects of voltage-gated ion channel modula-
tors on rat prostatic cancer cell proliferation: comparison of strongly and weakly
metastatic cell lines, Prostate 44 (2000) 61–76.
[69] M.E. Laniado, S.P. Fraser, M.B. Djamgoz, Voltage-gated K(+) channel activity
in human prostate cancer cell lines of markedly different metastatic potential:
distinguishing characteristics of PC-3 and LNCaP cells, Prostate 46 (2001)
262–274.
[70] M. Brevet, N. Haren, H. Sevestre, P. Merviel, H. Ouadid-Ahidouch, DNAmethylation
of K(v)1.3 potassium channel gene promoter is associatedwith poorly differentiat-
ed breast adenocarcinoma, Cell. Physiol. Biochem. 24 (2009) 25–32.
[71] S.H. Jang, K.S. Kang, P.D. Ryu, S.Y. Lee, Kv1.3 voltage-gated K(+) channel subunit as
a potential diagnostic marker and therapeutic target for breast cancer, BMB Rep. 42
(2009) 535–539.
[72] J.J. Pancrazio, I.A. Tabbara, Y.I. Kim, Voltage-activated K+ conductance and cell
proliferation in small-cell lung cancer, Anticancer Res. 13 (1993) 1231–1234.
[73] J. Bielanska, J. Hernandez-Losa, T.Moline, R. Somoza, S.R. Cajal, E. Condom, J.C. Ferreres,
A. Felipe, Increased voltage-dependent K(+) channel Kv1.3 andKv1.5 expression cor-
relates with leiomyosarcoma aggressiveness, Oncol. Lett. 4 (2012) 227–230.
[74] J.A. Grimes, S.P. Fraser, G.J. Stephens, J.E. Downing, M.E. Laniado, C.S. Foster, P.D.
Abel, M.B. Djamgoz, Differential expression of voltage-activated Na+ currents in
two prostatic tumour cell lines: contribution to invasiveness in vitro, FEBS Lett.
369 (1995) 290–294.
[75] M.E. Laniado, E.N. Lalani, S.P. Fraser, J.A. Grimes, G. Bhangal, M.B. Djamgoz, P.D.
Abel, Expression and functional analysis of voltage-activated Na+ channels in
human prostate cancer cell lines and their contribution to invasion in vitro, Am.
J. Pathol. 150 (1997) 1213–1221.
[76] S.P. Fraser, J.A. Grimes, J.K. Diss, D. Stewart, J.O. Dolly, M.B. Djamgoz, Predominant
expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell
lines: electrophysiological, pharmacological and molecular characterisation,
Pﬂugers Arch. 446 (2003) 559–571.[77] M. Brevet, A. Ahidouch, H. Sevestre, P. Merviel, Y. El Hiani, M. Robbe, H. Ouadid-
Ahidouch, Expression of K+ channels in normal and cancerous human breast,
Histol. Histopathol. 23 (2008) 965–972.
[78] X. Wang, V. Tryndyak, E.O. Apostolov, X. Yin, S.V. Shah, I.P. Pogribny, A.G.
Basnakian, Sensitivity of human prostate cancer cells to chemotherapeutic drugs
depends on EndoG expression regulated by promoter methylation, Cancer Lett.
270 (2008) 132–143.
[79] A. Vallejo-Gracia, J. Bielanska, J. Hernandez-Losa, J. Castellvi, M.C. Ruiz-Marcellan, S.
Ramon y Cajal, E. Condom, J. Manils, C. Soler, N. Comes, J.C. Ferreres, A. Felipe,
Emerging role for the voltage-dependent K+ channel Kv1.5 in B-lymphocyte
physiology: expression associated with human lymphoma malignancy, J. Leukoc.
Biol. 94 (2013) 779–789.
[80] I. Szabo, L. Leanza, E. Gulbins, M. Zoratti, Physiology of potassium channels in the
inner membrane of mitochondria, Pﬂugers Arch. 463 (2012) 231–246.
[81] I. Szabo, M. Zoratti, E. Gulbins, Contribution of voltage-gated potassium channels to
the regulation of apoptosis, FEBS Lett. 584 (2010) 2049–2056.
[82] R. Vicente, A. Escalada, N. Villalonga, L. Texido, M. Roura-Ferrer, M. Martin-Satue, C.
Lopez-Iglesias, C. Soler, C. Solsona, M.M. Tamkun, A. Felipe, Association of Kv1.5
and Kv1.3 contributes to the major voltage-dependent K+ channel in macro-
phages, J. Biol. Chem. 281 (2006) 37675–37685.
[83] E. Gulbins, N. Sassi, H. Grassme,M. Zoratti, I. Szabo, Role of Kv1.3mitochondrial po-
tassium channel in apoptotic signalling in lymphocytes, Biochim. Biophys. Acta
1797 (2010) 1251–1259.
[84] L. Leanza, L. Trentin, K.A. Becker, F. Frezzato, M. Zoratti, G. Semenzato, E. Gulbins, I.
Szabo, Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3,
as a new and selective therapeutic strategy in chronic lymphocytic leukemia, Leu-
kemia 27 (2013) 1782–1785.
[85] L. Leanza, M. Zoratti, E. Gulbins, I. Szabo, Induction of apoptosis in macro-
phages via Kv1.3 and Kv1.5 potassium channels, Curr. Med. Chem. 19 (2012)
5394–5404.
[86] Y. Cheng, E. Gulbins, D. Siemen, Activation of the permeability transition pore by
Bax via inhibition of the mitochondrial BK channel, Cell. Physiol. Biochem. 27
(2011) 191–200.
[87] Z. Rusznak, G. Bakondi, L. Kosztka, K. Pocsai, B. Dienes, J. Fodor, A. Telek, M. Gonczi,
G. Szucs, L. Csernoch, Mitochondrial expression of the two-pore domain TASK-3
channels in malignantly transformed and non-malignant human cells, Virchows
Arch. 452 (2008) 415–426.
[88] A. Arcangeli, O. Crociani, E. Lastraioli, A. Masi, S. Pillozzi, A. Becchetti, Targeting ion
channels in cancer: a novel frontier in antineoplastic therapy, Curr. Med. Chem. 16
(2009) 66–93.
[89] S. Grissmer, A.N. Nguyen, J. Aiyar, D.C. Hanson, R.J. Mather, G.A. Gutman, M.J.
Karmilowicz, D.D. Auperin, K.G. Chandy, Pharmacological characterization of ﬁve
cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably
expressed in mammalian cell lines, Mol. Pharmacol. 45 (1994) 1227–1234.
[90] J. Vennekamp, H. Wulff, C. Beeton, P.A. Calabresi, S. Grissmer, W. Hansel, K.G.
Chandy, Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodula-
tors, Mol. Pharmacol. 65 (2004) 1364–1374.
[91] R.J. Leonard, M.L. Garcia, R.S. Slaughter, J.P. Reuben, Selective blockers of voltage-
gated K+ channels depolarize human T lymphocytes: mechanism of the antipro-
liferative effect of charybdotoxin, Proc. Natl. Acad. Sci. U. S. A. 89 (1992)
10094–10098.
[92] M. Garcia-Calvo, R.J. Leonard, J. Novick, S.P. Stevens, W. Schmalhofer, G.J.
Kaczorowski, M.L. Garcia, Puriﬁcation, characterization, and biosynthesis of
margatoxin, a component of Centruroides margaritatus venom that selectively in-
hibits voltage-dependent potassium channels, J. Biol. Chem. 268 (1993)
18866–18874.
[93] M.D. Cahalan, K.G. Chandy, Ion channels in the immune system as targets for im-
munosuppression, Curr. Opin. Biotechnol. 8 (1997) 749–756.
[94] K.M. Mullen, M. Rozycka, H. Rus, L. Hu, C. Cudrici, E. Zafranskaia, M.W. Pennington,
D.C. Johns, S.I. Judge, P.A. Calabresi, Potassium channels Kv1.3 and Kv1.5 are
expressed on blood-derived dendritic cells in the central nervous system, Ann.
Neurol. 60 (2006) 118–127.
[95] M.M. Tamkun, K.M. Knoth, J.A. Walbridge, H. Kroemer, D.M. Roden, D.M. Glover,
Molecular cloning and characterization of two voltage-gated K+ channel cDNAs
from human ventricle, FASEB J. 5 (1991) 331–337.
[96] J. Bielanska, J. Hernandez-Losa, T. Moline, R. Somoza, Y.C.S. Ramon, E. Condom, J.C.
Ferreres, A. Felipe, Voltage-dependent potassium channels Kv1.3 and Kv1.5 in
human fetus, Cell. Physiol. Biochem. 26 (2010) 219–226.
[97] T.M. Olson, A.E. Alekseev, X.K. Liu, S. Park, L.V. Zingman, M. Bienengraeber, S.
Sattiraju, J.D. Ballew, A. Jahangir, A. Terzic, Kv1.5 channelopathy due to KCNA5
loss-of-function mutation causes human atrial ﬁbrillation, Hum. Mol. Genet. 15
(2006) 2185–2191.
[98] N.H. Nielsen, B.G. Winkel, J.K. Kanters, N. Schmitt, J. Hofman-Bang, H.S. Jensen, B.H.
Bentzen, B. Sigurd, L.A. Larsen, P.S. Andersen, S. Haunso, K. Kjeldsen, M. Grunnet, M.
Christiansen, S.P. Olesen, Mutations in the Kv1.5 channel gene KCNA5 in cardiac ar-
rest patients, Biochem. Biophys. Res. Commun. 354 (2007) 776–782.
[99] B. Attali, N. Wang, A. Kolot, A. Sobko, V. Cherepanov, B. Soliven, Characterization of
delayed rectiﬁer Kv channels in oligodendrocytes and progenitor cells, J. Neurosci.
17 (1997) 8234–8245.
[100] N. Villalonga, M. David, J. Bielanska, T. Gonzalez, D. Parra, C. Soler, N. Comes, C.
Valenzuela, A. Felipe, Immunomodulatory effects of diclofenac in leukocytes
through the targeting of Kv1.3 voltage-dependent potassium channels, Biochem.
Pharmacol. 80 (2010) 858–866.
[101] N. Villalonga, M. David, J. Bielanska, R. Vicente, N. Comes, C. Valenzuela, A. Felipe,
Immunomodulation of voltage-dependent K+ channels in macrophages: molecu-
lar and biophysical consequences, J. Gen. Physiol. 135 (2010) 135–147.
2489N. Comes et al. / Biochimica et Biophysica Acta 1848 (2015) 2477–2492[102] S.N. MacFarlane, H. Sontheimer, Modulation of Kv1.5 currents by Src tyrosine
phosphorylation: potential role in the differentiation of astrocytes, J. Neurosci. 20
(2000) 5245–5253.
[103] N. Villalonga, A. Escalada, R. Vicente, E. Sanchez-Tillo, A. Celada, C. Solsona, A.
Felipe, Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses
in macrophages, Biochem. Biophys. Res. Commun. 352 (2007) 913–918.
[104] S. Arvind, A. Arivazhagan, V. Santosh, B.A. Chandramouli, Differential expression of
a novel voltage gated potassium channel–Kv 1.5 in astrocytomas and its impact on
prognosis in glioblastoma, Br. J. Neurosurg. 26 (2012) 16–20.
[105] J.W. Warmke, B. Ganetzky, A family of potassium channel genes related to eag in
Drosophila and mammals, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3438–3442.
[106] C.K. Bauer, J.R. Schwarz, Physiology of EAG K+ channels, J. Membr. Biol. 182
(2001) 1–15.
[107] J. Ludwig, R. Weseloh, C. Karschin, Q. Liu, R. Netzer, B. Engeland, C. Stansfeld, O.
Pongs, Cloning and functional expression of rat eag2, a new member of the
ether-a-go-go family of potassium channels and comparison of its distribution
with that of eag1, Mol. Cell. Neurosci. 16 (2000) 59–70.
[108] M. Ju, D. Wray, Molecular identiﬁcation and characterisation of the human eag2
potassium channel, FEBS Lett. 524 (2002) 204–210.
[109] R. Schonherr, G. Gessner, K. Lober, S.H. Heinemann, Functional distinction of
human EAG1 and EAG2 potassium channels, FEBS Lett. 514 (2002) 204–208.
[110] L.A. Pardo, W. Stuhmer, Eag1 as a cancer target, Expert Opin. Ther. Targets 12
(2008) 837–843.
[111] T. Occhiodoro, L. Bernheim, J.H. Liu, P. Bijlenga, M. Sinnreich, C.R. Bader, J. Fischer-
Lougheed, Cloning of a human ether-a-go-go potassium channel expressed in
myoblasts at the onset of fusion, FEBS Lett. 434 (1998) 177–182.
[112] A. Bruggemann, W. Stuhmer, L.A. Pardo, Mitosis-promoting factor-mediated sup-
pression of a cloned delayed rectiﬁer potassium channel expressed in Xenopus oo-
cytes, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 537–542.
[113] L.A. Pardo, A. Bruggemann, J. Camacho, W. Stuhmer, Cell cycle-related changes in
the conducting properties of r-eag K+ channels, J. Cell Biol. 143 (1998) 767–775.
[114] J. Camacho, A. Sanchez, W. Stuhmer, L.A. Pardo, Cytoskeletal interactions deter-
mine the electrophysiological properties of human EAG potassium channels,
Pﬂugers Arch. 441 (2000) 167–174.
[115] A. Arcangeli, L. Bianchi, A. Becchetti, L. Faravelli, M. Coronnello, E. Mini, M. Olivotto, E.
Wanke, A novel inward-rectifying K+ current with a cell-cycle dependence governs
the resting potential of mammalian neuroblastoma cells, J. Physiol. 489 (Pt 2)
(1995) 455–471.
[116] A.S. Borowiec, F. Hague, N. Harir, S. Guenin, F. Guerineau, F. Gouilleux, M.
Roudbaraki, K. Lassoued, H. Ouadid-Ahidouch, IGF-1 activates hEAG K(+) chan-
nels through an Akt-dependent signaling pathway in breast cancer cells: role in
cell proliferation, J. Cell. Physiol. 212 (2007) 690–701.
[117] H. Ouadid-Ahidouch, A. Ahidouch, K+ channel expression in human breast cancer
cells: involvement in cell cycle regulation and carcinogenesis, J. Membr. Biol. 221
(2008) 1–6.
[118] B.R. Downie, A. Sanchez, H. Knotgen, C. Contreras-Jurado, M. Gymnopoulos, C.
Weber, W. Stuhmer, L.A. Pardo, Eag1 expression interferes with hypoxia homeo-
stasis and induces angiogenesis in tumors, J. Biol. Chem. 283 (2008) 36234–36240.
[119] J.R. Agarwal, F. Griesinger, W. Stuhmer, L.A. Pardo, The potassium channel Ether a
go-go is a novel prognostic factor with functional relevance in acute myeloid leu-
kemia, Mol. Cancer 9 (2010) 18.
[120] D. Gomez-Varela, E. Zwick-Wallasch, H. Knotgen, A. Sanchez, T. Hettmann, D.
Ossipov, R. Weseloh, C. Contreras-Jurado, M. Rothe, W. Stuhmer, L.A. Pardo, Mono-
clonal antibody blockade of the human Eag1 potassium channel function exerts
antitumor activity, Cancer Res. 67 (2007) 7343–7349.
[121] C. Weber, F. Mello de Queiroz, B.R. Downie, A. Suckow, W. Stuhmer, L.A. Pardo, Si-
lencing the activity and proliferative properties of the human EagI Potassium
Channel by RNA Interference, J. Biol. Chem. 281 (2006) 13030–13037.
[122] L.C. Cunha, E. Del Bel, L. Pardo, W. Stuhmer, D.E.A.R. Titze, RNA interference with
EAG1 enhances interferon gamma injury to glioma cells in vitro, Anticancer Res.
33 (2013) 865–870.
[123] B. Hemmerlein, R.M. Weseloh, F. Mello de Queiroz, H. Knotgen, A. Sanchez, M.E.
Rubio, S. Martin, T. Schliephacke, M. Jenke, R. Heinz Joachim, W. Stuhmer, L.A.
Pardo, Overexpression of Eag1 potassium channels in clinical tumours, Mol. Cancer
5 (2006) 41.
[124] R.E. Garcia-Ferreiro, D. Kerschensteiner, F. Major, F. Monje, W. Stuhmer, L.A. Pardo,
Mechanism of block of hEag1 K+ channels by imipramine and astemizole, J. Gen.
Physiol. 124 (2004) 301–317.
[125] Y.E. Alfaro-Mora, Human Eag1 potassium channel expression in lung cancer biop-
sies, in: P.P. AACR (Ed.)Proceedings of AACR-NCI-EORTC International Conference:
Molecular Targets and Cancer Therapeutics, Mol Cancer Ther, vol. 10, 2011, p. A nr
C13 (San Francisco, CA).
[126] H. Wulff, N.A. Castle, L.A. Pardo, Voltage-gated potassium channels as therapeutic
targets, Nat. Rev. Drug Discov. 8 (2009) 982–1001.
[127] D. Thomas, B. Gut, S. Karsai, A.B. Wimmer, K. Wu, G. Wendt-Nordahl, W. Zhang, S.
Kathofer, W. Schoels, H.A. Katus, J. Kiehn, C.A. Karle, Inhibition of cloned HERG po-
tassium channels by the antiestrogen tamoxifen, Naunyn Schmiedebergs Arch.
Pharmacol. 368 (2003) 41–48.
[128] D. Thomas, A.B. Wimmer, K. Wu, B.C. Hammerling, E.K. Ficker, Y.A. Kuryshev, J.
Kiehn, H.A. Katus, W. Schoels, C.A. Karle, Inhibition of human ether-a-go-go-relat-
ed gene potassium channels by alpha 1-adrenoceptor antagonists prazosin,
doxazosin, and terazosin, Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004)
462–472.
[129] D. Urrego, A.P. Tomczak, F. Zahed, W. Stuhmer, L.A. Pardo, Potassium channels in
cell cycle and cell proliferation, Philos. Trans. R. Soc. Lond. B Biol. Sci. 369 (2014)
20130094.[130] P. Bijlenga, T. Occhiodoro, J.H. Liu, C.R. Bader, L. Bernheim, J. Fischer-Lougheed, An
ether-a-go-go K+ current, Ih-eag, contributes to the hyperpolarization of human
fusion-competent myoblasts, J. Physiol. 512 (Pt 2) (1998) 317–323.
[131] S. Martin, C. Lino de Oliveira, F. Mello de Queiroz, L.A. Pardo,W. Stuhmer, E. Del Bel,
Eag1 potassium channel immunohistochemistry in the CNS of adult rat and select-
ed regions of human brain, Neuroscience 155 (2008) 833–844.
[132] R. Meyer, R. Schonherr, O. Gavrilova-Ruch, W. Wohlrab, S.H. Heinemann, Identiﬁ-
cation of ether a go-go and calcium-activated potassium channels in humanmela-
noma cells, J. Membr. Biol. 171 (1999) 107–115.
[133] O. Gavrilova-Ruch, K. Schonherr, G. Gessner, R. Schonherr, T. Klapperstuck, W.
Wohlrab, S.H. Heinemann, Effects of imipramine on ion channels and proliferation
of IGR1 melanoma cells, J. Membr. Biol. 188 (2002) 137–149.
[134] H. Ouadid-Ahidouch, X. Le Bourhis, M. Roudbaraki, R.A. Toillon, P. Delcourt, N.
Prevarskaya, Changes in the K+ current-density of MCF-7 cells during progression
through the cell cycle: possible involvement of a h-ether a-gogo K+ channel, Re-
ceptors Channels 7 (2001) 345–356.
[135] J. Ousingsawat,M. Spitzner, S. Puntheeranurak, L. Terracciano, L. Tornillo, L. Bubendorf,
K. Kunzelmann, R. Schreiber, Expression of voltage-gated potassium channels in
human and mouse colonic carcinoma, Clin. Cancer Res. 13 (2007) 824–831.
[136] X.W. Ding, H.S. Luo, X. Jin, J.J. Yan, Y.W. Ai, Aberrant expression of Eag1 potas-
sium channels in gastric cancer patients and cell lines, Med. Oncol. 24 (2007)
345–350.
[137] O. Crociani, L. Guasti, M. Balzi, A. Becchetti, E. Wanke, M. Olivotto, R.S. Wymore, A.
Arcangeli, Cell cycle-dependent expression of HERG1 and HERG1B isoforms in
tumor cells, J. Biol. Chem. 278 (2003) 2947–2955.
[138] X.W. Ding, X.G. Wang, H.S. Luo, S.Y. Tan, S. Gao, B. Luo, H. Jiang, Expression and
prognostic roles of Eag1 in resected esophageal squamous cell carcinomas, Dig.
Dis. Sci. 53 (2008) 2039–2044.
[139] X. Wu, D. Zhong, B. Lin, W. Zhai, Z. Ding, J. Wu, p38 MAPK regulates the expression
of ether a go-go potassium channel in human osteosarcoma cells, Radiol. Oncol. 47
(2013) 42–49.
[140] M.G. del Pliego, E. Aguirre-Benitez, K. Paisano-Ceron, I. Valdovinos-Ramirez, C.
Rangel-Morales, V. Rodriguez-Mata, C. Solano-Agama, D. Martin-Tapia, M.T. de la
Vega, M. Saldoval-Balanzario, J. Camacho, M.E. Mendoza-Garrido, Expression of
Eag1 K+ channel and ErbBs in human pituitary adenomas: cytoskeleton arrange-
ment patterns in cultured cells, Int. J. Clin. Exp. Pathol. 6 (2013) 458–468.
[141] S.T. Menendez, M.A. Villaronga, J.P. Rodrigo, S. Alvarez-Teijeiro, D. Garcia-
Carracedo, R.G. Urdinguio, M.F. Fraga, L.A. Pardo, C.G. Viloria, C. Suarez, J.M.
Garcia-Pedrero, Frequent aberrant expression of the human ether a go-go
(hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms
and clinical implications, J. Mol. Med. (Berl.) 90 (2012) 1173–1184.
[142] V. Asher, A. Warren, R. Shaw, H. Sowter, A. Bali, R. Khan, The role of Eag and HERG
channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer
cell line, Cancer Cell Int. 11 (2011) 6.
[143] S. Patt, K. Preussat, C. Beetz, R. Kraft, M. Schrey, R. Kalff, K. Schonherr, S.H.
Heinemann, Expression of ether a go-go potassium channels in human gliomas,
Neurosci. Lett. 368 (2004) 249–253.
[144] F. Mello de Queiroz, G. Suarez-Kurtz, W. Stuhmer, L.A. Pardo, Ether a go-go po-
tassium channel expression in soft tissue sarcoma patients, Mol. Cancer 5
(2006) 42.
[145] X.W. Ding, J.J. Yan, P. An, P. Lu, H.S. Luo, Aberrant expression of ether a go-go potas-
sium channel in colorectal cancer patients and cell lines, World J. Gastroenterol. 13
(2007) 1257–1261.
[146] G.A. Smith, H.W. Tsui, E.W. Newell, X. Jiang, X.P. Zhu, F.W. Tsui, L.C. Schlichter,
Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells,
J. Biol. Chem. 277 (2002) 18528–18534.
[147] M. Spitzner, J. Ousingsawat, K. Scheidt, K. Kunzelmann, R. Schreiber, Voltage-gated
K+ channels support proliferation of colonic carcinoma cells, FASEB J. 21 (2007)
35–44.
[148] L. Diaz, I. Ceja-Ochoa, I. Restrepo-Angulo, F. Larrea, E. Avila-Chavez, R. Garcia-
Becerra, E. Borja-Cacho, D. Barrera, E. Ahumada, P. Gariglio, E. Alvarez-Rios, R.
Ocadiz-Delgado, E. Garcia-Villa, E. Hernandez-Gallegos, I. Camacho-Arroyo, A.
Morales, D. Ordaz-Rosado, E. Garcia-Latorre, J. Escamilla, L.C. Sanchez-Pena, M.
Saqui-Salces, A. Gamboa-Dominguez, E. Vera, M. Uribe-Ramirez, J. Murbartian,
C.S. Ortiz, C. Rivera-Guevara, A. De Vizcaya-Ruiz, J. Camacho, Estrogens and
human papilloma virus oncogenes regulate human ether-a-go-go-1 potassium
channel expression, Cancer Res. 69 (2009) 3300–3307.
[149] A.K. Adams, T.M. Wise-Draper, S.I. Wells, Human papillomavirus induced transfor-
mation in cervical and head and neck cancers, Cancers (Basel) 6 (2014)
1793–1820.
[150] L. Lorenzon, M. Ferri, E. Pilozzi, M.R. Torrisi, V. Ziparo, D. French, Human papilloma-
virus and colorectal cancer: evidences and pitfalls of published literature, Int. J. Co-
lorectal Dis. 26 (2011) 135–142.
[151] A.R. Garbuglia, Human papillomavirus in head and neck cancer, Cancers (Basel) 6
(2014) 1705–1726.
[152] Y. Tolstov, B. Hadaschik, S. Pahernik, M. Hohenfellner, S. Duensing, Human papillo-
maviruses in urological malignancies: a critical assessment, Urol. Oncol. 32 (2014)
46 e19-27.
[153] A. Masi, A. Becchetti, R. Restano-Cassulini, S. Polvani, G. Hofmann, A.M. Buccoliero,
M. Paglierani, B. Pollo, G.L. Taddei, P. Gallina, N. Di Lorenzo, S. Franceschetti, E.
Wanke, A. Arcangeli, hERG1 channels are overexpressed in glioblastoma
multiforme and modulate VEGF secretion in glioblastoma cell lines, Br. J. Cancer
93 (2005) 781–792.
[154] Y. Chen, A. Sanchez, M.E. Rubio, T. Kohl, L.A. Pardo, W. Stuhmer, Functional
K(v)10.1 channels localize to the inner nuclear membrane, PLoS ONE 6 (2011)
e19257.
2490 N. Comes et al. / Biochimica et Biophysica Acta 1848 (2015) 2477–2492[155] Z. Pezer, D. Ugarkovic, Role of non-coding RNA and heterochromatin in aneuploidy
and cancer, Semin. Cancer Biol. 18 (2008) 123–130.
[156] C. Toral, M.E. Mendoza-Garrido, E. Azorin, E. Hernandez-Gallegos, J.C. Gomora, D.M.
Delgadillo, C. Solano-Agama, J. Camacho, Effect of extracellular matrix on adhesion,
viability, actin cytoskeleton and K+ currents of cells expressing human ether a go-
go channels, Life Sci. 81 (2007) 255–265.
[157] M. Spitzner, J.R. Martins, R.B. Soria, J. Ousingsawat, K. Scheidt, R. Schreiber, K.
Kunzelmann, Eag1 and Bestrophin 1 are up-regulated in fast-growing colonic can-
cer cells, J. Biol. Chem. 283 (2008) 7421–7428.
[158] A.P. Hegle, D.D. Marble, G.F. Wilson, A voltage-driven switch for ion-independent
signaling by ether-a-go-go K+ channels, Proc. Natl. Acad. Sci. U. S. A. 103 (2006)
2886–2891.
[159] V. Asher, H. Sowter, R. Shaw, A. Bali, R. Khan, Eag and HERG potassium channels as
novel therapeutic targets in cancer, World J. Surg. Oncol. 8 (2010) 113.
[160] F. Hartung, W. Stuhmer, L.A. Pardo, Tumor cell-selective apoptosis induction
through targeting of K(V)10.1 via bifunctional TRAIL antibody, Mol. Cancer 10
(2011) 109.
[161] M.C. Sanguinetti, C. Jiang, M.E. Curran, M.T. Keating, A mechanistic link between an
inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium
channel, Cell 81 (1995) 299–307.
[162] R. Schonherr, B. Rosati, S. Hehl, V.G. Rao, A. Arcangeli, M. Olivotto, S.H. Heinemann,
E. Wanke, Functional role of the slow activation property of ERG K+ channels, Eur.
J. Neurosci. 11 (1999) 753–760.
[163] T.V. McDonald, Z. Yu, Z. Ming, E. Palma,M.B.Meyers, K.W.Wang, S.A. Goldstein, G.I.
Fishman, A minK–HERG complex regulates the cardiac potassium current I(Kr),
Nature 388 (1997) 289–292.
[164] A.L. Pond, B.K. Scheve, A.T. Benedict, K. Petrecca, D.R. Van Wagoner, A. Shrier, J.M.
Nerbonne, Expression of distinct ERG proteins in rat, mouse, and human heart. Re-
lation to functional I(Kr) channels, J. Biol. Chem. 275 (2000) 5997–6006.
[165] A. Cherubini, G.L. Taddei, O. Crociani, M. Paglierani, A.M. Buccoliero, L. Fontana, I.
Noci, P. Borri, E. Borrani, M. Giachi, A. Becchetti, B. Rosati, E. Wanke, M. Olivotto,
A. Arcangeli, HERG potassium channels are more frequently expressed in human
endometrial cancer as compared to non-cancerous endometrium, Br. J. Cancer 83
(2000) 1722–1729.
[166] S. Pillozzi, M.F. Brizzi, M. Balzi, O. Crociani, A. Cherubini, L. Guasti, B. Bartolozzi, A.
Becchetti, E. Wanke, P.A. Bernabei, M. Olivotto, L. Pegoraro, A. Arcangeli, HERG po-
tassium channels are constitutively expressed in primary human acute myeloid
leukemias and regulate cell proliferation of normal and leukemic hemopoietic pro-
genitors, Leukemia 16 (2002) 1791–1798.
[167] E. Lastraioli, L. Guasti, O. Crociani, S. Polvani, G. Hofmann, H. Witchel, L. Bencini, M.
Calistri, L. Messerini, M. Scatizzi, R. Moretti, E. Wanke, M. Olivotto, G. Mugnai, A.
Arcangeli, herg1 gene and HERG1 protein are overexpressed in colorectal cancers
and regulate cell invasion of tumor cells, Cancer Res. 64 (2004) 606–611.
[168] A. Arcangeli, Expression and role of hERG channels in cancer cells, Novartis Found.
Symp. 266 (2005) 225–232 (discussion 232–224).
[169] X.W. Ding, W.B. Yang, S. Gao, W. Wang, Z. Li, W.M. Hu, J.J. Li, H.S. Luo, Prognostic sig-
niﬁcance of hERG1 expression in gastric cancer, Dig. Dis. Sci. 55 (2010) 1004–1010.
[170] X.D. Shao, K.C. Wu, X.Z. Guo, M.J. Xie, J. Zhang, D.M. Fan, Expression and signiﬁ-
cance of HERG protein in gastric cancer, Cancer Biol. Ther. 7 (2008) 45–50.
[171] L.A. Pardo, W. Stuhmer, Eag1: an emerging oncological target, Cancer Res. 68
(2008) 1611–1613.
[172] H. Ouadid-Ahidouch, F. Chaussade, M. Roudbaraki, C. Slomianny, E. Dewailly, P.
Delcourt, N. Prevarskaya, KV1.1 K(+) channels identiﬁcation in human breast car-
cinoma cells: involvement in cell proliferation, Biochem. Biophys. Res. Commun.
278 (2000) 272–277.
[173] X.D. Shao, K.C. Wu, Z.M. Hao, L. Hong, J. Zhang, D.M. Fan, The potent inhibitory ef-
fects of cisapride, a speciﬁc blocker for human ether-a-go-go-related gene (HERG)
channel, on gastric cancer cells, Cancer Biol. Ther. 4 (2005) 295–301.
[174] J. Zhao, X.L. Wei, Y.S. Jia, J.Q. Zheng, Silencing of herg gene by shRNA inhibits SH-
SY5Y cell growth in vitro and in vivo, Eur. J. Pharmacol. 579 (2008) 50–57.
[175] G. Glassmeier, K. Hempel, I. Wulfsen, C.K. Bauer, U. Schumacher, J.R. Schwarz, Inhi-
bition of HERG1 K+ channel protein expression decreases cell proliferation of
human small cell lung cancer cells, Pﬂugers Arch. 463 (2012) 365–376.
[176] E. Afrasiabi, M. Hietamaki, T. Viitanen, P. Sukumaran, N. Bergelin, K. Tornquist, Ex-
pression and signiﬁcance of HERG (KCNH2) potassium channels in the regulation
of MDA-MB-435S melanoma cell proliferation and migration, Cell. Signal. 22
(2010) 57–64.
[177] J.L. Overholt, E. Ficker, T. Yang, H. Shams, G.R. Bright, N.R. Prabhakar, HERG-Like po-
tassium current regulates the resting membrane potential in glomus cells of the
rabbit carotid body, J. Neurophysiol. 83 (2000) 1150–1157.
[178] O. Crociani, F. Zanieri, S. Pillozzi, E. Lastraioli, M. Stefanini, A. Fiore, A. Fortunato, M.
D'Amico, M. Masselli, E. De Lorenzo, L. Gasparoli, M. Chiu, O. Bussolati, A. Becchetti,
A. Arcangeli, hERG1 channels modulate integrin signaling to trigger angiogenesis
and tumor progression in colorectal cancer, Sci. Rep. 3 (2013) 3308.
[179] A. Becchetti, A. Arcangeli, Integrins and ion channels in cell migration: implications
for neuronal development, wound healing and metastatic spread, Adv. Exp. Med.
Biol. 674 (2010) 107–123.
[180] S. Pillozzi, M.F. Brizzi, P.A. Bernabei, B. Bartolozzi, R. Caporale, V. Basile, V. Boddi, L.
Pegoraro, A. Becchetti, A. Arcangeli, VEGFR-1 (FLT-1), beta1 integrin, and hERG K+
channel for a macromolecular signaling complex in acute myeloid leukemia: role
in cell migration and clinical outcome, Blood 110 (2007) 1238–1250.
[181] S. Pillozzi, M. Masselli, E. De Lorenzo, B. Accordi, E. Cilia, O. Crociani, A. Amedei, M.
Veltroni, M. D'Amico, G. Basso, A. Becchetti, D. Campana, A. Arcangeli, Chemother-
apy resistance in acute lymphoblastic leukemia requires hERG1 channels and is
overcome by hERG1 blockers, Blood 117 (2011) 902–914.[182] G. Hofmann, P.A. Bernabei, O. Crociani, A. Cherubini, L. Guasti, S. Pillozzi, E.
Lastraioli, S. Polvani, B. Bartolozzi, V. Solazzo, L. Gragnani, P. Deﬁlippi, B. Rosati,
E. Wanke, M. Olivotto, A. Arcangeli, HERG K+ channels activation during
beta(1) integrin-mediated adhesion to ﬁbronectin induces an up-regulation of
alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1, J. Biol.
Chem. 276 (2001) 4923–4931.
[183] H. Li, Y.M. Du, L. Guo, S. Jie, S. Zhang, W. Du, X. Chen, W. Liu, L. Fan, J. Zhu, A. Zou, S.
Huang, The role of hERG1 K+ channels and a functional link between hERG1 K+
channels and SDF-1 in acute leukemic cell migration, Exp. Cell Res. 315 (2009)
2256–2264.
[184] M.Y. Asghar, T. Viitanen, K. Kemppainen, K. Tornquist, Sphingosine 1-phosphate
and human ether-a'-go-go-related gene potassium channels modulate migration
in human anaplastic thyroid cancer cells, Endocr. Relat. Cancer 19 (2012) 667–680.
[185] A. Arcangeli, A. Becchetti, A. Mannini, G. Mugnai, P. De Filippi, G. Tarone, M.R. Del
Bene, E. Barletta, E. Wanke, M. Olivotto, Integrin-mediated neurite outgrowth in
neuroblastoma cells depends on the activation of potassium channels, J. Cell Biol.
122 (1993) 1131–1143.
[186] N. Chiesa, B. Rosati, A. Arcangeli, M. Olivotto, E. Wanke, A novel role for HERG K+
channels: spike-frequency adaptation, J. Physiol. 501 (Pt 2) (1997) 313–318.
[187] A. Cherubini, G. Hofmann, S. Pillozzi, L. Guasti, O. Crociani, E. Cilia, P. Di Stefano, S.
Degani, M. Balzi, M. Olivotto, E. Wanke, A. Becchetti, P. Deﬁlippi, R. Wymore, A.
Arcangeli, Human ether-a-go-go-related gene 1 channels are physically linked to
beta1 integrins and modulate adhesion-dependent signaling, Mol. Biol. Cell 16
(2005) 2972–2983.
[188] A. Arcangeli, A. Becchetti, Complex functional interaction between integrin recep-
tors and ion channels, Trends Cell Biol. 16 (2006) 631–639.
[189] M.J. Saganich, E. Machado, B. Rudy, Differential expression of genes encoding
subthreshold-operating voltage-gated K+ channels in brain, J. Neurosci. 21
(2001) 4609–4624.
[190] A. Arcangeli, A. Becchetti, A. Cherubini,O. Crociani, P. Deﬁlippi, L. Guasti, G.Hofmann, S.
Pillozzi, M. Olivotto, E. Wanke, Physical and functional interaction between integrins
and hERG potassium channels, Biochem. Soc. Trans. 32 (2004) 826–827.
[191] L. Bianchi, A. Arcangeli, P. Bartolini, G. Mugnai, E. Wanke, M. Olivotto, An inward
rectiﬁer K+ current modulates in neuroblastoma cells the tyrosine phosphoryla-
tion of the pp125FAK and associated proteins: role in neuritogenesis, Biochem.
Biophys. Res. Commun. 210 (1995) 823–829.
[192] A. Arcangeli, S. Pillozzi, A. Becchetti, Targeting ion channels in leukemias: a new
challenge for treatment, Curr. Med. Chem. 19 (2012) 683–696.
[193] S. Pillozzi, A. Arcangeli, Physical and functional interaction between integrins and
hERG1 channels in cancer cells, Adv. Exp. Med. Biol. 674 (2010) 55–67.
[194] U. Banderali, D. Belke, A. Singh, A. Jayanthan, W.R. Giles, A. Narendran, Curcumin
blocks Kv11.1 (erg) potassium current and slows proliferation in the infant acute
monocytic leukemia cell line THP-1, Cell. Physiol. Biochem. 28 (2011) 1169–1180.
[195] E. Lastraioli, A. Taddei, L. Messerini, C.E. Comin, M. Festini, M. Giannelli, A.
Tomezzoli, M. Paglierani, G. Mugnai, G. De Manzoni, P. Bechi, A. Arcangeli,
hERG1 channels in human esophagus: evidence for their aberrant expression in
the malignant progression of Barrett's esophagus, J. Cell. Physiol. 209 (2006)
398–404.
[196] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000) 57–70.
[197] A. Fiore, L. Carraresi, A. Morabito, S. Polvani, A. Fortunato, E. Lastraioli, A.P. Femia, E.
De Lorenzo, G. Caderni, A. Arcangeli, Characterization of hERG1 channel role in
mouse colorectal carcinogenesis, Cancer Med. 2 (2013) 583–594.
[198] T. Suzuki, K. Takimoto, Selective expression of HERG and Kv2 channels inﬂuences
proliferation of uterine cancer cells, Int. J. Oncol. 25 (2004) 153–159.
[199] J. Roy, B. Vantol, E.A. Cowley, J. Blay, P. Linsdell, Pharmacological separation of
hEAG and hERG K+ channel function in the human mammary carcinoma cell
line MCF-7, Oncol. Rep. 19 (2008) 1511–1516.
[200] A. Sette, J. Spadavecchia, J. Landoulsi, S. Casale, B. Haye, O. Crociani, A. Arcangeli,
Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiO nanoparticles
for targeting pancreatic ductal adenocarcinoma cells, J. Nanoparticle Res. 15
(2013) 2111.
[201] M. D'Amico, L. Gasparoli, A. Arcangeli, Potassium channels: novel emerging bio-
markers and targets for therapy in cancer, Recent Pat. Anticancer Drug Discov. 8
(2013) 53–65.
[202] J.S. Mitcheson, hERG potassium channels and the structural basis of drug-induced
arrhythmias, Chem. Res. Toxicol. 21 (2008) 1005–1010.
[203] L. Guasti, O. Crociani, E. Redaelli, S. Pillozzi, S. Polvani, M. Masselli, T. Mello, A. Galli,
A. Amedei, R.S.Wymore, E.Wanke, A. Arcangeli, Identiﬁcation of a posttranslation-
al mechanism for the regulation of hERG1 K+ channel expression and hERG1 cur-
rent density in tumor cells, Mol. Cell. Biol. 28 (2008) 5043–5060.
[204] S.B. Ganapathi, M. Kester, K.S. Elmslie, State-dependent block of HERG potassium
channels by R-roscovitine: implications for cancer therapy, Am. J. Physiol. Cell
Physiol. 296 (2009) C701–C710.
[205] K.A. Ketchum, W.J. Joiner, A.J. Sellers, L.K. Kaczmarek, S.A. Goldstein, A new family
of outwardly rectifying potassium channel proteins with two pore domains in tan-
dem, Nature 376 (1995) 690–695.
[206] S. Rajan, E. Wischmeyer, G. Xin Liu, R. Preisig-Muller, J. Daut, A. Karschin, C. Derst,
TASK-3, a novel tandem pore domain acid-sensitive K+ channel. An extracellular
histiding as pH sensor, J. Biol. Chem. 275 (2000) 16650–16657.
[207] S.A. Goldstein, D. Bockenhauer, I. O'Kelly, N. Zilberberg, Potassium leak channels
and the KCNK family of two-P-domain subunits, Nat. Rev. Neurosci. 2 (2001)
175–184.
[208] S.G. Meuth, M.I. Aller, T. Munsch, T. Schuhmacher, T. Seidenbecher, P. Meuth, C.
Kleinschnitz, H.C. Pape, H. Wiendl, W. Wisden, T. Budde, The contribution of
TWIK-related acid-sensitive K+-containing channels to the function of dorsal
2491N. Comes et al. / Biochimica et Biophysica Acta 1848 (2015) 2477–2492lateral geniculate thalamocortical relay neurons, Mol. Pharmacol. 69 (2006)
1468–1476.
[209] S.G. Meuth, T. Budde, T. Kanyshkova, T. Broicher, T. Munsch, H.C. Pape, Contribu-
tion of TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 channels
to the control of activity modes in thalamocortical neurons, J. Neurosci. 23
(2003) 6460–6469.
[210] P.M. Larkman, E.M. Perkins, A TASK-like pH- and amine-sensitive ‘leak’ K+ con-
ductance regulates neonatal rat facial motoneuron excitability in vitro, Eur. J.
Neurosci. 21 (2005) 679–691.
[211] A. Olschewski, Y. Li, B. Tang, J. Hanze, B. Eul, R.M. Bohle, J. Wilhelm, R.E. Morty, M.E.
Brau, E.K. Weir, G. Kwapiszewska, W. Klepetko, W. Seeger, H. Olschewski, Impact
of TASK-1 in human pulmonary artery smooth muscle cells, Circ. Res. 98 (2006)
1072–1080.
[212] S.N. Skatchkov, M.J. Eaton, Y.M. Shuba, Y.V. Kucheryavykh, C. Derst, R.W. Veh, A.
Wurm, I. Iandiev, T. Pannicke, A. Bringmann, A. Reichenbach, Tandem-pore domain
potassium channels are functionally expressed in retinal (Muller) glial cells, Glia
53 (2006) 266–276.
[213] E.M. Talley, Q. Lei, J.E. Sirois, D.A. Bayliss, TASK-1, a two-pore domain K+ channel,
is modulated by multiple neurotransmitters in motoneurons, Neuron 25 (2000)
399–410.
[214] F. Duprat, F. Lesage, M. Fink, R. Reyes, C. Heurteaux, M. Lazdunski, TASK, a human
background K+ channel to sense external pH variations near physiological pH,
EMBO J. 16 (1997) 5464–5471.
[215] C.G. Chapman, H.J. Meadows, R.J. Godden, D.A. Campbell, M. Duckworth, R.E.
Kelsell, P.R. Murdock, A.D. Randall, G.I. Rennie, I.S. Gloger, Cloning, localisation
and functional expression of a novel human, cerebellum speciﬁc, two pore domain
potassium channel, Brain Res. Mol. Brain Res. 82 (2000) 74–83.
[216] Y. Kim, H. Bang, D. Kim, TASK-3, a new member of the tandem pore K(+) channel
family, J. Biol. Chem. 275 (2000) 9340–9347.
[217] K.J. Buckler, B.A. Williams, E. Honore, An oxygen-, acid- and anaesthetic-sensitive
TASK-like background potassium channel in rat arterial chemoreceptor cells, J.
Physiol. 525 (Pt 1) (2000) 135–142.
[218] T. Budde, P. Coulon, M. Pawlowski, P. Meuth, T. Kanyshkova, A. Japes, S.G. Meuth,
H.C. Pape, Reciprocal modulation of I (h) and I (TASK) in thalamocortical relay neu-
rons by halothane, Pﬂugers Arch. 456 (2008) 1061–1073.
[219] H.J. Meadows, A.D. Randall, Functional characterisation of human TASK-3, an acid-
sensitive two-pore domain potassium channel, Neuropharmacology 40 (2001)
551–559.
[220] E.M. Talley, D.A. Bayliss, Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potas-
sium channels: volatile anesthetics and neurotransmitters share amolecular site of
action, J. Biol. Chem. 277 (2002) 17733–17742.
[221] A.J. Patel, E. Honore, F. Lesage, M. Fink, G. Romey, M. Lazdunski, Inhalational anes-
thetics activate two-pore-domain background K+ channels, Nat. Neurosci. 2
(1999) 422–426.
[222] D.A. Bayliss, P.Q. Barrett, Emerging roles for two-pore-domain potassium
channels and their potential therapeutic impact, Trends Pharmacol. Sci. 29
(2008) 566–575.
[223] I. Kovacs, K. Pocsai, G. Czifra, L. Sarkadi, G. Szucs, Z. Nemes, Z. Rusznak, TASK-3 im-
munoreactivity shows differential distribution in the human gastrointestinal tract,
Virchows Arch. 446 (2005) 402–410.
[224] G. Czirjak, T. Fischer, A. Spat, F. Lesage, P. Enyedi, TASK (TWIK-related acid-
sensitive K+ channel) is expressed in glomerulosa cells of rat adrenal cortex
and inhibited by angiotensin II, Mol. Endocrinol. 14 (2000) 863–874.
[225] G. Czirjak, P. Enyedi, TASK-3 dominates the background potassium conductance in
rat adrenal glomerulosa cells, Mol. Endocrinol. 16 (2002) 621–629.
[226] A.D. O'Connell, M.J. Morton, M. Hunter, Two-pore domain K+ channels-molecular
sensors, Biochim. Biophys. Acta 1566 (2002) 152–161.
[227] J. Chemin, C. Girard, F. Duprat, F. Lesage, G. Romey, M. Lazdunski, Mechanisms un-
derlying excitatory effects of group I metabotropic glutamate receptors via inhibi-
tion of 2P domain K+ channels, EMBO J. 22 (2003) 5403–5411.
[228] M.I. Aller, E.L. Veale, A.M. Linden, C. Sandu, M. Schwaninger, L.J. Evans, E.R. Korpi, A.
Mathie, W. Wisden, S.G. Brickley, Modifying the subunit composition of TASK
channels alters the modulation of a leak conductance in cerebellar granule neu-
rons, J. Neurosci. 25 (2005) 11455–11467.
[229] J. Han, C. Gnatenco, C.D. Sladek, D. Kim, Background and tandem-pore potassium
channels in magnocellular neurosecretory cells of the rat supraoptic nucleus, J.
Physiol. 546 (2003) 625–639.
[230] M.E. Hartness, A. Lewis, G.J. Searle, I. O'Kelly, C. Peers, P.J. Kemp, Combined anti-
sense and pharmacological approaches implicate hTASK as an airway
O(2) sensing K(+) channel, J. Biol. Chem. 276 (2001) 26499–26508.
[231] C.P. Washburn, J.E. Sirois, E.M. Talley, P.G. Guyenet, D.A. Bayliss, Serotonergic raphe
neurons express TASK channel transcripts and a TASK-like pH- and halothane-
sensitive K+ conductance, J. Neurosci. 22 (2002) 1256–1265.
[232] K. Pocsai, L. Kosztka, G. Bakondi, M. Gonczi, J. Fodor, B. Dienes, P. Szentesi, I. Kovacs,
R. Feniger-Barish, E. Kopf, D. Zharhary, G. Szucs, L. Csernoch, Z. Rusznak, Melanoma
cells exhibit strong intracellular TASK-3-speciﬁc immunopositivity in both tissue
sections and cell culture, Cell. Mol. Life Sci. 63 (2006) 2364–2376.
[233] C.J. Kim, Y.G. Cho, S.W. Jeong, Y.S. Kim, S.Y. Kim, S.W. Nam, S.H. Lee, N.J. Yoo, J.Y.
Lee, W.S. Park, Altered expression of KCNK9 in colorectal cancers, APMIS 112
(2004) 588–594.
[234] L. Pei, O. Wiser, A. Slavin, D. Mu, S. Powers, L.Y. Jan, T. Hoey, Oncogenic potential of
TASK3 (Kcnk9) depends on K+ channel function, Proc. Natl. Acad. Sci. U. S. A. 100
(2003) 7803–7807.
[235] S. Harguindey, G. Orive, J. Luis Pedraz, A. Paradiso, S.J. Reshkin, The role of pH dy-
namics and the Na+/H+ antiporter in the etiopathogenesis and treatment ofcancer. Two faces of the same coin–one single nature, Biochim. Biophys. Acta
1756 (2005) 1–24.
[236] M. Hoglund, D. Gisselsson, G.B. Hansen, T. Sall, F. Mitelman, M. Nilbert, Dissecting
karyotypic patterns in colorectal tumors: two distinct but overlapping pathways
in the adenoma-carcinoma transition, Cancer Res. 62 (2002) 5939–5946.
[237] I. Lauritzen, M. Zanzouri, E. Honore, F. Duprat, M.U. Ehrengruber, M. Lazdunski, A.J.
Patel, K+-dependent cerebellar granule neuron apoptosis. Role of task leak K+
channels, J. Biol. Chem. 278 (2003) 32068–32076.
[238] C. Liu, J.F. Cotten, J.A. Schuyler, C.S. Fahlman, J.D. Au, P.E. Bickler, C.S. Yost, Protective
effects of TASK-3 (KCNK9) and related 2P K channels during cellular stress, Brain
Res. 1031 (2005) 164–173.
[239] A. Innamaa, L. Jackson, V. Asher, G. Van Shalkwyk, A. Warren, D. Hay, A. Bali, H.
Sowter, R. Khan, Expression and prognostic signiﬁcance of the oncogenic K2P po-
tassium channel KCNK9 (TASK-3) in ovarian carcinoma, Anticancer Res. 33 (2013)
1401–1408.
[240] L. Kosztka, Z. Rusznak, D. Nagy, Z. Nagy, J. Fodor, G. Szucs, A. Telek, M. Gonczi, O.
Ruzsnavszky, N. Szentandrassy, L. Csernoch, Inhibition of TASK-3 (KCNK9) channel
biosynthesis changes cell morphology and decreases both DNA content and mito-
chondrial function of melanoma cells maintained in cell culture, Melanoma Res. 21
(2011) 308–322.
[241] A. Szewczyk, W. Jarmuszkiewicz, W.S. Kunz, Mitochondrial potassium channels,
IUBMB Life 61 (2009) 134–143.
[242] G.W. Lee, H.S. Park, E.J. Kim, Y.W. Cho, G.T. Kim, Y.J. Mun, E.J. Choi, J.S. Lee, J. Han, D.
Kang, Reduction of breast cancer cell migration via up-regulation of TASK-3 two-
pore domain K+ channel, Acta Physiol. (Oxf.) 204 (2012) 513–524.
[243] E.K. Hoffmann, C. Hougaard, Intracellular signalling involved in activation of the
volume-sensitive K+ current in Ehrlich ascites tumour cells, Comp. Biochem.
Physiol. A Mol. Integr. Physiol. 130 (2001) 355–366.
[244] C.R. Ries, E. Puil, Ionic mechanism of isoﬂurane's actions on thalamocortical neu-
rons, J. Neurophysiol. 81 (1999) 1802–1809.
[245] B. Musset, S.G. Meuth, G.X. Liu, C. Derst, S. Wegner, H.C. Pape, T. Budde, R. Preisig-
Muller, J. Daut, Effects of divalent cations and spermine on the K+ channel TASK-3
and on the outward current in thalamic neurons, J. Physiol. 572 (2006) 639–657.
[246] F. Maingret, A.J. Patel, M. Lazdunski, E. Honore, The endocannabinoid anandamide
is a direct and selective blocker of the background K(+) channel TASK-1, EMBO J.
20 (2001) 47–54.
[247] M. Gomez-Angelats, C.D. Bortner, J.A. Cidlowski, Cell volume regulation in immune
cell apoptosis, Cell Tissue Res. 301 (2000) 33–42.
[248] S.P. Yu, L.M. Canzoniero, D.W. Choi, Ion homeostasis and apoptosis, Curr. Opin. Cell
Biol. 13 (2001) 405–411.
[249] S.P. Yu, Regulation and critical role of potassium homeostasis in apoptosis, Prog.
Neurobiol. 70 (2003) 363–386.
[250] S.P. Yu, D.W. Choi, Ions, cell volume, and apoptosis, Proc. Natl. Acad. Sci. U. S. A. 97
(2000) 9360–9362.
[251] Y. Okada, E. Maeno, Apoptosis, cell volume regulation and volume-regulatory
chloride channels, Comp. Biochem. Physiol. A Mol. Integr. Physiol. 130 (2001)
377–383.
[252] C.H. Kindler, C.S. Yost, A.T. Gray, Local anesthetic inhibition of baseline potassium
channels with two pore domains in tandem, Anesthesiology 90 (1999) 1092–1102.
[253] J.E. Sirois, Q. Lei, E.M. Talley, C. Lynch III, D.A. Bayliss, The TASK-1 two-pore domain
K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics,
J. Neurosci. 20 (2000) 6347–6354.
[254] A.D.Medhurst, G. Rennie, C.G. Chapman, H. Meadows, M.D. Duckworth, R.E. Kelsell,
I.I. Gloger, M.N. Pangalos, Distribution analysis of human two pore domain potas-
sium channels in tissues of the central nervous system and periphery, Brain Res.
Mol. Brain Res. 86 (2001) 101–114.
[255] J. Han, J. Truell, C. Gnatenco, D. Kim, Characterization of four types of background
potassium channels in rat cerebellar granule neurons, J. Physiol. 542 (2002)
431–444.
[256] A. Barbuti, S. Ishii, T. Shimizu, R.B. Robinson, S.J. Feinmark, Block of the background
K(+) channel TASK-1 contributes to arrhythmogenic effects of platelet-activating
factor, Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H2024–H2030.
[257] D. Leonoudakis, A.T. Gray, B.D. Winegar, C.H. Kindler, M. Harada, D.M. Taylor, R.A.
Chavez, J.R. Forsayeth, C.S. Yost, An open rectiﬁer potassium channel with two pore
domains in tandem cloned from rat cerebellum, J. Neurosci. 18 (1998) 868–877.
[258] G. Czirjak, P. Enyedi, Formation of functional heterodimers between the TASK-1
and TASK-3 two-pore domain potassium channel subunits, J. Biol. Chem. 277
(2002) 5426–5432.
[259] D. Kim, E.J. Cavanaugh, I. Kim, J.L. Carroll, Heteromeric TASK-1/TASK-3 is the major
oxygen-sensitive background K+ channel in rat carotid body glomus cells, J. Phys-
iol. 587 (2009) 2963–2975.
[260] F. Lesage, M. Lazdunski, Molecular and functional properties of two-pore-domain
potassium channels, Am. J. Physiol. Ren. Physiol. 279 (2000) F793–F801.
[261] D. Cavalieri, P. Dolara, E. Mini, C. Luceri, C. Castagnini, S. Toti, K. Maciag, C. De
Filippo, S. Nobili, M. Morganti, C. Napoli, G. Tonini, M. Baccini, A. Biggeri, F.
Tonelli, R. Valanzano, C. Orlando, S. Gelmini, F. Cianchi, L. Messerini, L. Luzzatto,
Analysis of gene expression proﬁles reveals novel correlations with the clinical
course of colorectal cancer, Oncol. Res. 16 (2007) 535–548.
[262] I. Voloshyna, A. Besana, M. Castillo, T. Matos, I.B. Weinstein, M. Mansukhani, R.B.
Robinson, C. Cordon-Cardo, S.J. Feinmark, TREK-1 is a novel molecular target in
prostate cancer, Cancer Res. 68 (2008) 1197–1203.
[263] K.H. Taylor, K.E. Pena-Hernandez, J.W. Davis, G.L. Arthur, D.J. Duff, H. Shi, F.B.
Rahmatpanah, O. Sjahputera, C.W. Caldwell, Large-scale CpG methylation analysis
identiﬁes novel candidate genes and reveals methylation hotspots in acute lym-
phoblastic leukemia, Cancer Res. 67 (2007) 2617–2625.
2492 N. Comes et al. / Biochimica et Biophysica Acta 1848 (2015) 2477–2492[264] E.M. Talley, G. Solorzano,Q. Lei, D. Kim,D.A. Bayliss, Cns distributionofmembers of the
two-pore-domain (KCNK) potassium channel family, J. Neurosci. 21 (2001)
7491–7505.
[265] A.J. Patel, E. Honore, F. Maingret, F. Lesage, M. Fink, F. Duprat, M. Lazdunski, A
mammalian two pore domain mechano-gated S-like K+ channel, EMBO J. 17
(1998) 4283–4290.
[266] F. Maingret, I. Lauritzen, A.J. Patel, C. Heurteaux, R. Reyes, F. Lesage, M. Lazdunski, E.
Honore, TREK-1 is a heat-activated background K(+) channel, EMBO J. 19 (2000)
2483–2491.
[267] F. Maingret, A.J. Patel, F. Lesage, M. Lazdunski, E. Honore, Mechano- or acid stimu-
lation, two interactive modes of activation of the TREK-1 potassium channel, J. Biol.
Chem. 274 (1999) 26691–26696.
[268] M. Fink, F. Lesage, F. Duprat, C. Heurteaux, R. Reyes, M. Fosset, M. Lazdunski, A neu-
ronal two P domain K+ channel stimulated by arachidonic acid and polyunsatu-
rated fatty acids, EMBO J. 17 (1998) 3297–3308.
[269] F. Maingret, E. Honore, M. Lazdunski, A.J. Patel, Molecular basis of the voltage-
dependent gating of TREK-1, a mechano-sensitive K(+) channel, Biochem.
Biophys. Res. Commun. 292 (2002) 339–346.
[270] D. Bockenhauer, N. Zilberberg, S.A. Goldstein, KCNK2: reversible conversion of a
hippocampal potassium leak into a voltage-dependent channel, Nat. Neurosci. 4
(2001) 486–491.
[271] H. Liu, J.A. Enyeart, J.J. Enyeart, Potent inhibition of native TREK-1 K+ channels by
selected dihydropyridine Ca2+ channel antagonists, J. Pharmacol. Exp. Ther. 323
(2007) 39–48.
[272] J.J. Enyeart, L. Xu, S. Danthi, J.A. Enyeart, An ACTH- and ATP-regulated background
K+ channel in adrenocortical cells is TREK-1, J. Biol. Chem. 277 (2002)
49186–49199.
[273] E. Honore, F. Maingret, M. Lazdunski, A.J. Patel, An intracellular proton sensor com-
mands lipid- and mechano-gating of the K(+) channel TREK-1, EMBO J. 21 (2002)
2968–2976.
[274] F. Lang, M. Foller, K.S. Lang, P.A. Lang, M. Ritter, E. Gulbins, A. Vereninov, S.M.
Huber, Ion channels in cell proliferation and apoptotic cell death, J. Membr. Biol.
205 (2005) 147–157.
[275] S. Ohya, K. Kimura, S. Niwa, A. Ohno, Y. Kojima, S. Sasaki, K. Kohri, Y. Imaizumi,
Malignancy grade-dependent expression of K+-channel subtypes in human pros-
tate cancer, J. Pharmacol. Sci. 109 (2009) 148–151.
[276] A. Innamaa, L. Jackson, V. Asher, G. van Schalkwyk, A. Warren, A. Keightley, D. Hay,
A. Bali, H. Sowter, R. Khan, Expression and effects of modulation of the K2Ppotassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal
human ovary and epithelial ovarian cancer, Clin. Transl. Oncol. 15 (2013) 910–918.
[277] D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-Xuan, J.Y. Delattre, Primary
brain tumours in adults, Lancet 379 (2012) 1984–1996.
[278] J.F. Whitﬁeld, R.P. Bird, B.R. Chakravarthy, R.J. Isaacs, P. Morley, Calcium-cell cycle
regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter, J.
Cell. Biochem. Suppl. 22 (1995) 74–91.
[279] L. Santella, K. Kyozuka, L. De Riso, E. Carafoli, Calcium, protease action, and the reg-
ulation of the cell cycle, Cell Calcium 23 (1998) 123–130.
[280] M. Yang, W.J. Brackenbury, Membrane potential and cancer progression, Front.
Physiol. 4 (2013) 185.
[281] B. Rouzaire-Dubois, J.M. Dubois, K+ channel block-induced mammalian neuro-
blastoma cell swelling: a possible mechanism to inﬂuence proliferation, J. Physiol.
510 (Pt 1) (1998) 93–102.
[282] B. Rouzaire-Dubois, J.B. Milandri, S. Bostel, J.M. Dubois, Control of cell proliferation
by cell volume alterations in rat C6 glioma cells, Pﬂugers Arch. 440 (2000)
881–888.
[283] A. Arcangeli, Ion channels and transporters in cancer. 3. Ion channels in the tumor
cell–microenvironment cross talk, Am. J. Physiol. Cell Physiol. 301 (2011)
C762–C771.
[284] M. Hammadi, V. Chopin, F. Matifat, I. Dhennin-Duthille, M. Chasseraud, H. Sevestre,
H. Ouadid-Ahidouch, Human ether a-gogo K(+) channel 1 (hEag1) regulates
MDA-MB-231 breast cancer cell migration through Orai1-dependent calcium
entry, J. Cell. Physiol. 227 (2012) 3837–3846.
[285] M. Brevet, D. Fucks, D. Chatelain, J.M. Regimbeau, R. Delcenserie, H. Sevestre, H.
Ouadid-Ahidouch, Deregulation of 2 potassium channels in pancreas adenocarci-
nomas: implication of KV1.3 gene promoter methylation, Pancreas 38 (2009)
649–654.
[286] M.S. Cicek, D.C. Koestler, B.L. Fridley, K.R. Kalli, S.M. Armasu, M.C. Larson, C. Wang,
S.J. Winham, R.A. Vierkant, D.N. Rider, M.S. Block, B. Klotzle, G. Konecny, B.J.
Winterhoff, H. Hamidi, V. Shridhar, J.B. Fan, D.W. Visscher, J.E. Olson, L.C.
Hartmann, M. Bibikova, J. Chien, J.M. Cunningham, E.L. Goode, Epigenome-wide
ovarian cancer analysis identiﬁes a methylation proﬁle differentiating clear-cell
histology with epigenetic silencing of the HERG K+ channel, Hum. Mol. Genet.
22 (2013) 3038–3047.
